Precision control systems for tissue visualization and manipulation assemblies

Description

FIELD OF THE INVENTION

The present invention relates generally to medical devices used for accessing, visualizing, and/or treating regions of tissue within a body. More particularly, the present invention relates to systems for controlling and navigating devices used to directly visualize and/or manipulate tissue regions within a body lumen which are generally difficult to access and/or image.

BACKGROUND OF THE INVENTION

Conventional devices for visualizing interior regions of a body lumen are known. For example, ultrasound devices have been used to produce images from within a body in vivo. Ultrasound has been used both with and without contrast agents, which typically enhance ultrasound-derived images.

Other conventional methods have utilized catheters or probes having position sensors deployed within the body lumen, such as the interior of a cardiac chamber. These types of positional sensors are typically used to determine the movement of a cardiac tissue surface or the electrical activity within the cardiac tissue. When a sufficient number of points have been sampled by the sensors, a “map” of the cardiac tissue may be generated.

Another conventional device utilizes an inflatable balloon which is typically introduced intravascularly in a deflated state and then inflated against the tissue region to be examined. Imaging is typically accomplished by an optical fiber or other apparatus such us electronic chips for viewing the tissue through the membrane(s) of the inflated balloon. Moreover, the balloon must generally be inflated for imaging. Other conventional balloons utilize a cavity or depression formed at a distal end of the inflated balloon. This cavity or depression is pressed against the tissue to be examined and is flushed with a clear fluid to provide a clear pathway through the blood.

However, such imaging balloons have many inherent disadvantages. For instance, such balloons generally require that the balloon be inflated to a relatively large size which may undesirably displace surrounding tissue and interfere with fine positioning of the imaging system against the tissue. Moreover, the working area created by such inflatable balloons are generally cramped and limited in size. Furthermore, inflated balloons may be susceptible to pressure changes in the surrounding fluid. For example, if the environment surrounding the inflated balloon undergoes pressure changes, e.g., during systolic and diastolic pressure cycles in a beating heart, the constant pressure change may affect the inflated balloon volume and its positioning to produce unsteady or undesirable conditions for optimal tissue imaging.

Accordingly, these types of imaging modalities are generally unable to provide desirable images useful for sufficient diagnosis and therapy of the endoluminal structure, due in part to factors such as dynamic forces generated by the natural movement of the heart. Moreover, anatomic structures within the body can occlude or obstruct the image acquisition process. Also, the presence and movement of opaque bodily fluids such as blood generally make in vivo imaging of tissue regions within the heart difficult.

Other external imaging modalities are also conventionally utilized. For example, computed tomography (CT) and magnetic resonance imaging (MRI) are typical modalities which are widely used to obtain images of body lumens such as the interior chambers of the heart. However, such imaging modalities fail to provide real-time imaging for intra-operative therapeutic procedures. Fluoroscopic imaging, for instance, is widely used to identify anatomic landmarks within the heart and other regions of the body. However, fluoroscopy fails to provide an accurate image of the tissue quality or surface and also fails to provide for instrumentation for performing tissue manipulation or other therapeutic procedures upon the visualized tissue regions. In addition, fluoroscopy provides a shadow of the intervening tissue onto a plate or sensor when it may be desirable to view the intraluminal surface of the tissue to diagnose pathologies or to perform some form of therapy on it.

Thus, a tissue imaging system which is able to provide real-time in vivo images of tissue regions within body lumens such as the heart through opaque media such as blood and which also provide instruments for therapeutic procedures upon the visualized tissue are desirable.

BRIEF SUMMARY OF THE INVENTION

A tissue imaging and manipulation apparatus that may be utilized for procedures within a body lumen, such as the heart, in which visualization of the surrounding tissue is made difficult, if not impossible, by medium contained within the lumen such as blood, is described below. Generally, such a tissue imaging and manipulation apparatus comprises an optional delivery catheter or sheath through which a deployment catheter and imaging hood may be advanced for placement against or adjacent to the tissue to be imaged.

The deployment catheter may define a fluid delivery lumen therethrough as well as an imaging lumen within which an optical imaging fiber or assembly may be disposed for imaging tissue. When deployed, the imaging hood may be expanded into any number of shapes, e.g., cylindrical, conical as shown, semi-spherical, etc., provided that an open area or field is defined by the imaging hood. The open area is the area within which the tissue region of interest may be imaged. The imaging hood may also define an atraumatic contact lip or edge for placement or abutment against the tissue region of interest. Moreover, the distal end of the deployment catheter or separate manipulatable catheters may be articulated through various controlling mechanisms such as push-pull wires manually or via computer control

The deployment catheter may also be stabilized relative to the tissue surface through various methods. For instance, inflatable stabilizing balloons positioned along a length of the catheter may be utilized, or tissue engagement anchors may be passed through or along the deployment catheter for temporary engagement of the underlying tissue.

In operation, after the imaging hood has been deployed, fluid may be pumped at a positive pressure through the fluid delivery lumen until the fluid fills the open area completely and displaces any blood from within the open area. The fluid may comprise any biocompatible fluid, e.g., saline, water, plasma, Fluorinert™, etc., which is sufficiently transparent to allow for relatively undistorted visualization through the fluid. The fluid may be pumped continuously or intermittently to allow for image capture by an optional processor which may be in communication with the assembly.

In an exemplary variation for imaging tissue surfaces within a heart chamber containing blood, the tissue imaging and treatment system may generally comprise a catheter body having a lumen defined therethrough, a visualization element disposed adjacent the catheter body, the visualization element having a field of view, a transparent fluid source in fluid communication with the lumen, and a barrier or membrane extendable from the catheter body to localize, between the visualization element and the field of view, displacement of blood by transparent fluid that flows from the lumen, and a piercing instrument translatable through the displaced blood for piercing into the tissue surface within the field of view.

The imaging hood may be formed into any number of configurations and the imaging assembly may also be utilized with any number of therapeutic tools which may be deployed through the deployment catheter.

Moreover, the imaging hood may be utilized with various catheter control assemblies to provide for precise catheter motion. For instance, robotically-controlled catheter systems may be utilized with the imaging hood and various instruments delivered through the hood. Alternatively, magnetic navigational systems may also be utilized to control and/or locate a hood within the patient body.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1A shows a side view of one variation of a tissue imaging apparatus during deployment from a sheath or delivery catheter.

FIG. 1B shows the deployed tissue imaging apparatus of FIG. 1A having an optionally expandable hood or sheath attached to an imaging and/or diagnostic catheter.

FIG. 1C shows an end view of a deployed imaging apparatus.

FIGS. 1D to 1F show the apparatus of FIGS. 1A to 1C with an additional lumen, e.g., for passage of a guidewire therethrough.

FIGS. 2A and 2B show one example of a deployed tissue imager positioned against or adjacent to the tissue to be imaged and a flow of fluid, such as saline, displacing blood from within the expandable hood.

FIG. 3A shows an articulatable imaging assembly which may be manipulated via push-pull wires or by computer control.

FIGS. 3B and 3C show steerable instruments, respectively, where an articulatable delivery catheter may be steered within the imaging hood or a distal portion of the deployment catheter itself may be steered.

FIGS. 4A to 4C show side and cross-sectional end views, respectively, of another variation having an off-axis imaging capability.

FIG. 5 shows an illustrative view of an example of a tissue imager advanced intravascularly within a heart for imaging tissue regions within an atrial chamber.

FIGS. 6A to 6C illustrate deployment catheters having one or more optional inflatable balloons or anchors for stabilizing the device during a procedure.

FIGS. 7A and 7B illustrate a variation of an anchoring mechanism such as a helical tissue piercing device for temporarily stabilizing the imaging hood relative to a tissue surface.

FIG. 7C shows another variation for anchoring the imaging hood having one or more tubular support members integrated with the imaging hood; each support members may define a lumen therethrough for advancing a helical tissue anchor within.

FIG. 8A shows an illustrative example of one variation of how a tissue imager may be utilized with an imaging device.

FIG. 8B shows a further illustration of a hand-held variation of the fluid delivery and tissue manipulation system.

FIGS. 9A to 9C illustrate an example of capturing several images of the tissue at multiple regions.

FIGS. 10A and 10B show charts illustrating how fluid pressure within the imaging hood may be coordinated with the surrounding blood pressure; the fluid pressure in the imaging hood may be coordinated with the blood pressure or it may be regulated based upon pressure feedback from the blood.

FIG. 11A shows a side view of another variation of a tissue imager having an imaging balloon within an expandable hood.

FIG. 11B shows another variation of a tissue imager utilizing a translucent or transparent imaging balloon.

FIG. 12A shows another variation in which a flexible expandable or distensible membrane may be incorporated within the imaging hood to alter the volume of fluid dispensed.

FIGS. 12B and 12C show another variation in which the imaging hood may be partially or selectively deployed from the catheter to alter the area of the tissue being visualized as well as the volume of the dispensed fluid.

FIGS. 13A and 13B show exemplary side and cross-sectional views, respectively, of another variation in which the injected fluid may be drawn back into the device for minimizing fluid input into a body being treated.

FIGS. 14A to 14D show various configurations and methods for configuring an imaging hood into a low-profile for delivery and/or deployment.

FIGS. 15A and 15B show an imaging hood having an helically expanding frame or support.

FIGS. 16A and 16B show another imaging hood having one or more hood support members, which are pivotably attached at their proximal ends to deployment catheter, integrated with a hood membrane.

FIGS. 17A and 17B show yet another variation of the imaging hood having at least two or more longitudinally positioned support members supporting the imaging hood membrane where the support members are movable relative to one another via a torquing or pulling or pushing force.

FIGS. 18A and 18B show another variation where a distal portion of the deployment catheter may have several pivoting members which form a tubular shape in its low profile configuration.

FIGS. 19A and 19B show another variation where the distal portion of deployment catheter may be fabricated from a flexible metallic or polymeric material to form a radially expanding hood.

FIGS. 20A and 20B show another variation where the imaging hood may be formed from a plurality of overlapping hood members which overlie one another in an overlapping pattern.

FIGS. 21A and 21B show another example of an expandable hood which is highly conformable against tissue anatomy with varying geography.

FIG. 22A shows yet another example of an expandable hood having a number of optional electrodes placed about the contact edge or lip of the hood for sensing tissue contact or detecting arrhythmias.

FIG. 22B shows another variation for conforming the imaging hood against the underlying tissue where an inflatable contact edge may be disposed around the circumference of the imaging hood.

FIG. 23 shows a variation of the system which may be instrumented with a transducer for detecting the presence of blood seeping back into the imaging hood.

FIGS. 24A and 24B show variations of the imaging hood instrumented with sensors for detecting various physical parameters; the sensors may be instrumented around the outer surface of the imaging hood and also within the imaging hood.

FIGS. 25A and 25B show a variation where the imaging hood may have one or more LEDs over the hood itself for providing illumination of the tissue to be visualized.

FIGS. 26A and 26B show another variation in which a separate illumination tool having one or more LEDs mounted thereon may be utilized within the imaging hood.

FIG. 27 shows one example of how a therapeutic tool may be advanced through the tissue imager for treating a tissue region of interest.

FIG. 28 shows another example of a helical therapeutic tool for treating the tissue region of interest.

FIG. 29 shows a variation of how a therapeutic tool may be utilized with an expandable imaging balloon.

FIGS. 30A and 30B show alternative configurations for therapeutic instruments which may be utilized; one variation is shown having an angled instrument arm and another variation is shown with an off-axis instrument arm.

FIGS. 31A to 31C show side and end views, respectively, of an imaging system which may be utilized with an ablation probe.

FIGS. 32A and 32B show side and end views, respectively, of another variation of the imaging hood with an ablation probe, where the imaging hood may be enclosed for regulating a temperature of the underlying tissue.

FIGS. 33A and 33B show an example in which the imaging fluid itself may be altered in temperature to facilitate various procedures upon the underlying tissue.

FIGS. 34A and 34B show an example of a laser ring generator which may be utilized with the imaging system and an example for applying the laser ring generator within the left atrium of a heart for treating atrial fibrillation.

FIGS. 35A to 35C show an example of an extendible cannula generally comprising an elongate tubular member which may be positioned within the deployment catheter during delivery and then projected distally through the imaging hood and optionally beyond.

FIGS. 36A and 36B show side and end views, respectively, of an imaging hood having one or more tubular support members integrated with the hood for passing instruments or tools therethrough for treatment upon the underlying tissue.

FIGS. 37A and 37B illustrate how an imaging device may be guided within a heart chamber to a region of interest utilizing a lighted probe positioned temporarily within, e.g., a lumen of the coronary sinus.

FIGS. 38A and 38B show an imaging hood having a removable disk-shaped member for implantation upon the tissue surface.

FIGS. 39A to 39C show one method for implanting the removable disk of FIGS. 38A and 38B.

FIGS. 40A and 40B illustrate an imaging hood having a deployable anchor assembly attached to the tissue contact edge and an assembly view of the anchors and the suture or wire connected to the anchors, respectively

FIGS. 41A to 41D show one method for deploying the anchor assembly of FIGS. 40A and 40B for closing an opening or wound.

FIG. 42 shows another variation in which the imaging system may be fluidly coupled to a dialysis unit for filtering a patient's blood.

FIGS. 43A and 43B show a variation of the deployment catheter having a first deployable hood and a second deployable hood positioned distal to the first hood; the deployment catheter may also have a side-viewing imaging element positioned between the first and second hoods for imaging tissue between the expanded hoods.

FIGS. 44A and 44B show side and end views, respectively, of a deployment catheter having a side-imaging balloon in an un-inflated low-profile configuration.

FIGS. 45A to 45C show side, top, and end views, respectively, of the inflated balloon of FIGS. 44A and 44B defining a visualization field in the inflated balloon.

FIGS. 46A and 46B show side and cross-sectional end views, respectively, for one method of use in visualizing a lesion upon a vessel wall within the visualization field of the inflated balloon from FIGS. 45A to 45C.

FIGS. 47A and 47B show assembly views of examples of a robotically-controlled guide instrument for precisely controlling a position of a hood.

FIG. 47C illustrates an example of how a robotic guide instrument may be utilized with a visualization system.

FIGS. 48A and 48B show perspective views of a variation of a robotic control assembly showing base having four proximal drive assemblies and the imaging hood positioned at a distal end of the catheter.

FIG. 48C illustrates a perspective view of another variation of a robotic control assembly having an inflatable imaging balloon assembly.

FIG. 49 shows a partially disassembled perspective view of the precision control driver.

FIG. 50 shows a perspective assembly view of the guide instrument mounted upon an instrument driver.

FIG. 51 shows the partially disassembled perspective view of the catheter instrument driver.

FIGS. 52A and 52B show perspective views of another variation of the tissue visualization catheter with precision control steering.

FIG. 53 illustrates an example of a simplified assembly view of the mechanisms within the control drive unit for controlling the articulation of hood.

FIGS. 54A and 54B show an assembled view and exploded assembly view, respectively, of a tissue visualization hood having a pivotably articulating steering assembly.

FIGS. 55A to 55C show an assembled view, detailed spine, and exploded assembly view, respectively, of a tissue visualization hood utilizing steerable spine segments.

FIGS. 56A to 56C show another variation in an assembled view, detailed spine, and exploded assembly view, respectively, of a tissue visualization hood also utilizing steerable spine segments.

FIG. 57A shows a perspective view of a hood having a ferromagnetic ring attached circumferentially around the lip of the hood.

FIG. 57B shows a perspective view of an example of a magnetic navigation system which may be used to steer the imaging hood through the patient body.

FIG. 58 shows a perspective view of another variation of the tissue visualization catheter which is configured to detect the position and/or orientation of the hood via ultrasound transducers and having a magnetic ring circumferentially positioned about the lip of the hood.

FIG. 59 shows a perspective view of another variation of the tissue visualization catheter which is configured to detect the position and/or orientation of the hood via ultrasound transducers and having electromagnetic coils wound about one or more struts.

FIG. 60 shows a perspective view of another variation of the tissue visualization catheter having a ferromagnetic disc positioned within the hood.

FIG. 61 shows a perspective view of a position sensor assembly which may be utilized to detect an orientation and/or location of the hood within the body as well as to draw the hood against an internal tissue region.

FIG. 62 illustrates an example of triangulation of the transducers to determine the orientation and position of the hood within a patient body.

FIGS. 63A to 63C illustrate an example for orienting and drawing a hood within a left atrial chamber against the tissue surface to “walk” the hood along the tissue wall to visually survey the underlying surface.

FIG. 64 illustrates another example where a catheter having several transducers may be positioned within the coronary sinus to communicate with the hood.

DETAILED DESCRIPTION OF THE INVENTION

A tissue-imaging and manipulation apparatus described below is able to provide real-time images in vivo of tissue regions within a body lumen such as a heart, which is filled with blood flowing dynamically therethrough and is also able to provide intravascular tools and instruments for performing various procedures upon the imaged tissue regions. Such an apparatus may be utilized for many procedures, e.g., facilitating transseptal access to the left atrium, cannulating the coronary sinus, diagnosis of valve regurgitation/stenosis, valvuloplasty, atrial appendage closure, arrhythmogenic focus ablation, among other procedures.

One variation of a tissue access and imaging apparatus is shown in the detail perspective views of FIGS. 1A to 1C. As shown in FIG. 1A, tissue imaging and manipulation assembly 10 may be delivered intravascularly through the patient's body in a low-profile configuration via a delivery catheter or sheath 14. In the case of treating tissue, such as the mitral valve located at the outflow tract of the left atrium of the heart, it is generally desirable to enter or access the left atrium while minimizing trauma to the patient. To non-operatively effect such access, one conventional approach involves puncturing the intra-atrial septum from the right atrial chamber to the left atrial chamber in a procedure commonly called a transseptal procedure or septostomy. For procedures such as percutaneous valve repair and replacement, transseptal access to the left atrial chamber of the heart may allow for larger devices to be introduced into the venous system than can generally be introduced percutaneously into the arterial system.

When the imaging and manipulation assembly 10 is ready to be utilized for imaging tissue, imaging hood 12 may be advanced relative to catheter 14 and deployed from a distal opening of catheter 14, as shown by the arrow. Upon deployment, imaging hood 12 may be unconstrained to expand or open into a deployed imaging configuration, as shown in FIG. 1B. Imaging hood 12 may be fabricated from a variety of pliable or conformable biocompatible material including but not limited to, e.g., polymeric, plastic, or woven materials. One example of a woven material is Kevlar® (E. I. du Pont de Nemours, Wilmington, Del.), which is an aramid and which can be made into thin, e.g., less than 0.001 in., materials which maintain enough integrity for such applications described herein. Moreover, the imaging hood 12 may be fabricated from a translucent or opaque material and in a variety of different colors to optimize or attenuate any reflected lighting from surrounding fluids or structures, i.e., anatomical or mechanical structures or instruments. In either case, imaging hood 12 may be fabricated into a uniform structure or a scaffold-supported structure, in which case a scaffold made of a shape memory alloy, such as Nitinol, or a spring steel, or plastic, etc., may be fabricated and covered with the polymeric, plastic, or woven material. Hence, imaging hood 12 may comprise any of a wide variety of barriers or membrane structures, as may generally be used to localize displacement of blood or the like from a selected volume of a body lumen or heart chamber. In exemplary embodiments, a volume within an inner surface 13 of imaging hood 12 will be significantly less than a volume of the hood 12 between inner surface 13 and outer surface 11.

Imaging hood 12 may be attached at interface 24 to a deployment catheter 16 which may be translated independently of deployment catheter or sheath 14. Attachment of interface 24 may be accomplished through any number of conventional methods. Deployment catheter 16 may define a fluid delivery lumen 18 as well as an imaging lumen 20 within which an optical imaging fiber or assembly may be disposed for imaging tissue. When deployed, imaging hood 12 may expand into any number of shapes, e.g., cylindrical, conical as shown, semi-spherical, etc., provided that an open area or field 26 is defined by imaging hood 12. The open area 26 is the area within which the tissue region of interest may be imaged. Imaging hood 12 may also define an atraumatic contact lip or edge 22 for placement or abutment against the tissue region of interest. Moreover, the diameter of imaging hood 12 at its maximum fully deployed diameter, e.g., at contact lip or edge 22, is typically greater relative to a diameter of the deployment catheter 16 (although a diameter of contact lip or edge 22 may be made to have a smaller or equal diameter of deployment catheter 16). For instance, the contact edge diameter may range anywhere from 1 to 5 times (or even greater, as practicable) a diameter of deployment catheter 16. FIG. 1C shows an end view of the imaging hood 12 in its deployed configuration. Also shown are the contact lip or edge 22 and fluid delivery lumen 18 and imaging lumen 20.

The imaging and manipulation assembly 10 may additionally define a guidewire lumen therethrough, e.g., a concentric or eccentric lumen, as shown in the side and end views, respectively, of FIGS. 1D to 1F. The deployment catheter 16 may define guidewire lumen 19 for facilitating the passage of the system over or along a guidewire 17, which may be advanced intravascularly within a body lumen. The deployment catheter 16 may then be advanced over the guidewire 17, as generally known in the art.

In operation, after imaging hood 12 has been deployed, as in FIG. 1B, and desirably positioned against the tissue region to be imaged along contact edge 22, the displacing fluid may be pumped at positive pressure through fluid delivery lumen 18 until the fluid fills open area 26 completely and displaces any fluid 28 from within open area 26. The displacing fluid flow may be laminarized to improve its clearing effect and to help prevent blood from re-entering the imaging hood 12. Alternatively, fluid flow may be started before the deployment takes place. The displacing fluid, also described herein as imaging fluid, may comprise any biocompatible fluid, e.g., saline, water, plasma, etc., which is sufficiently transparent to allow for relatively undistorted visualization through the fluid. Alternatively or additionally, any number of therapeutic drugs may be suspended within the fluid or may comprise the fluid itself which is pumped into open area 26 and which is subsequently passed into and through the heart and the patient body.

As seen in the example of FIGS. 2A and 2B, deployment catheter 16 may be manipulated to position deployed imaging hood 12 against or near the underlying tissue region of interest to be imaged, in this example a portion of annulus A of mitral valve MV within the left atrial chamber. As the surrounding blood 30 flows around imaging hood 12 and within open area 26 defined within imaging hood 12, as seen in FIG. 2A, the underlying annulus A is obstructed by the opaque blood 30 and is difficult to view through the imaging lumen 20. The translucent fluid 28, such as saline, may then be pumped through fluid delivery lumen 18, intermittently or continuously, until the blood 30 is at least partially, and preferably completely, displaced from within open area 26 by fluid 28, as shown in FIG. 2B.

Although contact edge 22 need not directly contact the underlying tissue, it is at least preferably brought into close proximity to the tissue such that the flow of clear fluid 28 from open area 26 may be maintained to inhibit significant backflow of blood 30 back into open area 26. Contact edge 22 may also be made of a soft elastomeric material such as certain soft grades of silicone or polyurethane, as typically known, to help contact edge 22 conform to an uneven or rough underlying anatomical tissue surface. Once the blood 30 has been displaced from imaging hood 12, an image may then be viewed of the underlying tissue through the clear fluid 30. This image may then be recorded or available for real-time viewing for performing a therapeutic procedure. The positive flow of fluid 28 may be maintained continuously to provide for clear viewing of the underlying tissue. Alternatively, the fluid 28 may be pumped temporarily or sporadically only until a clear view of the tissue is available to be imaged and recorded, at which point the fluid flow 28 may cease and blood 30 may be allowed to seep or flow back into imaging hood 12. This process may be repeated a number of times at the same tissue region or at multiple tissue regions.

In desirably positioning the assembly at various regions within the patient body, a number of articulation and manipulation controls may be utilized. For example, as shown in the articulatable imaging assembly 40 in FIG. 3A, one or more push-pull wires 42 may be routed through deployment catheter 16 for steering the distal end portion of the device in various directions 46 to desirably position the imaging hood 12 adjacent to a region of tissue to be visualized. Depending upon the positioning and the number of push-pull wires 42 utilized, deployment catheter 16 and imaging hood 12 may be articulated into any number of configurations 44. The push-pull wire or wires 42 may be articulated via their proximal ends from outside the patient body manually utilizing one or more controls. Alternatively, deployment catheter 16 may be articulated by computer control, as further described below.

Additionally or alternatively, an articulatable delivery catheter 48, which may be articulated via one or more push-pull wires and having an imaging lumen and one or more working lumens, may be delivered through the deployment catheter 16 and into imaging hood 12. With a distal portion of articulatable delivery catheter 48 within imaging hood 12, the clear displacing fluid may be pumped through delivery catheter 48 or deployment catheter 16 to clear the field within imaging hood 12. As shown in FIG. 3B, the articulatable delivery catheter 48 may be articulated within the imaging hood to obtain a better image of tissue adjacent to the imaging hood 12. Moreover, articulatable delivery catheter 48 may be articulated to direct an instrument or tool passed through the catheter 48, as described in detail below, to specific areas of tissue imaged through imaging hood 12 without having to reposition deployment catheter 16 and re-clear the imaging field within hood 12.

Alternatively, rather than passing an articulatable delivery catheter 48 through the deployment catheter 16, a distal portion of the deployment catheter 16 itself may comprise a distal end 49 which is articulatable within imaging hood 12, as shown in FIG. 3C. Directed imaging, instrument delivery, etc., may be accomplished directly through one or more lumens within deployment catheter 16 to specific regions of the underlying tissue imaged within imaging hood 12.

Visualization within the imaging hood 12 may be accomplished through an imaging lumen 20 defined through deployment catheter 16, as described above. In such a configuration, visualization is available in a straight-line manner, i.e., images are generated from the field distally along a longitudinal axis defined by the deployment catheter 16. Alternatively or additionally, an articulatable imaging assembly having a pivotable support member 50 may be connected to, mounted to, or otherwise passed through deployment catheter 16 to provide for visualization off-axis relative to the longitudinal axis defined by deployment catheter 16, as shown in FIG. 4A. Support member 50 may have an imaging element 52. e.g., a CCD or CMOS imager or optical fiber, attached at its distal end with its proximal end connected to deployment catheter 16 via a pivoting connection 54.

If one or more optical fibers are utilized for imaging, the optical fibers 58 may be passed through deployment catheter 16, as shown in the cross-section of FIG. 4B, and routed through the support member 50. The use of optical fibers 58 may provide for increased diameter sizes of the one or several lumens 56 through deployment catheter 16 for the passage of diagnostic and/or therapeutic tools therethrough. Alternatively, electronic chips, such as a charge coupled device (CCD) or a CMOS imager, which are typically known, may be utilized in place of the optical fibers 58, in which case the electronic imager may be positioned in the distal portion of the deployment catheter 16 with electric wires being routed proximally through the deployment catheter 16. Alternatively, the electronic imagers may be wirelessly coupled to a receiver for the wireless transmission of images. Additional optical fibers or light emitting diodes (LEDs) can be used to provide lighting for the image or operative theater, as described below in further detail. Support member 50 may be pivoted via connection 54 such that the member 50 can be positioned in a low-profile configuration within channel or groove 60 defined in a distal portion of catheter 16, as shown in the cross-section of FIG. 4C. During intravascular delivery of deployment catheter 16 through the patient body, support member 50 can be positioned within channel or groove 60 with imaging hood 12 also in its low-profile configuration. During visualization, imaging hood 12 may be expanded into its deployed configuration and support member 50 may be deployed into its off-axis configuration for imaging the tissue adjacent to hood 12, as in FIG. 4A. Other configurations for support member 50 for off-axis visualization may be utilized, as desired.

FIG. 5 shows an illustrative cross-sectional view of a heart H having tissue regions of interest being viewed via an imaging assembly 10. In this example, delivery catheter assembly 70 may be introduced percutaneously into the patient's vasculature and advanced through the superior vena cava SVC and into the right atrium RA. The delivery catheter or sheath 72 may be articulated through the atrial septum AS and into the left atrium LA for viewing or treating the tissue, e.g., the annulus A, surrounding the mitral valve MV. As shown, deployment catheter 16 and imaging hood 12 may be advanced out of delivery catheter 72 and brought into contact or in proximity to the tissue region of interest. In other examples, delivery catheter assembly 70 may be advanced through the inferior vena cava IVC, if so desired. Moreover, other regions of the heart H, e.g., the right ventricle RV or left ventricle LV, may also be accessed and imaged or treated by imaging assembly 10.

In accessing regions of the heart H or other parts of the body, the delivery catheter or sheath 14 may comprise a conventional intra-vascular catheter or an endoluminal delivery device. Alternatively, robotically-controlled delivery catheters may also be optionally utilized with the imaging assembly described herein, in which case a computer-controller 74 may be used to control the articulation and positioning of the delivery catheter 14. An example of a robotically-controlled delivery catheter which may be utilized is described in further detail in US Pat. Pub. 2002/0087169 A1 to Brock et al. entitled “Flexible Instrument”, which is incorporated herein by reference in its entirety. Other robotically-controlled delivery catheters manufactured by Hansen Medical, Inc. (Mountain View, Calif.) may also be utilized with the delivery catheter 14, as described in further detail below.

To facilitate stabilization of the deployment catheter 16 during a procedure, one or more inflatable balloons or anchors 76 may be positioned along the length of catheter 16, as shown in FIG. 6A. For example, when utilizing a transseptal approach across the atrial septum AS into the left atrium LA, the inflatable balloons 76 may be inflated from a low-profile into their expanded configuration to temporarily anchor or stabilize the catheter 16 position relative to the heart H. FIG. 6B shows a first balloon 78 inflated while FIG. 6C also shows a second balloon 80 inflated proximal to the first balloon 78. In such a configuration, the septal wall AS may be wedged or sandwiched between the balloons 78, 80 to temporarily stabilize the catheter 16 and imaging hood 12. A single balloon 78 or both balloons 78, 80 may be used. Other alternatives may utilize expandable mesh members, malecots, or any other temporary expandable structure. After a procedure has been accomplished, the balloon assembly 76 may be deflated or re-configured into a low-profile for removal of the deployment catheter 16.

To further stabilize a position of the imaging hood 12 relative to a tissue surface to be imaged, various anchoring mechanisms may be optionally employed for temporarily holding the imaging hood 12 against the tissue. Such anchoring mechanisms may be particularly useful for imaging tissue which is subject to movement, e.g., when imaging tissue within the chambers of a beating heart. A tool delivery catheter 82 having at least one instrument lumen and an optional visualization lumen may be delivered through deployment catheter 16 and into an expanded imaging hood 12. As the imaging hood 12 is brought into contact against a tissue surface T to be examined, anchoring mechanisms such as a helical tissue piercing device 84 may be passed through the tool delivery catheter 82, as shown in FIG. 7A, and into imaging hood 12.

The helical tissue engaging device 84 may be torqued from its proximal end outside the patient body to temporarily anchor itself into the underlying tissue surface T. Once embedded within the tissue T, the helical tissue engaging device 84 may be pulled proximally relative to deployment catheter 16 while the deployment catheter 16 and imaging hood 12 are pushed distally, as indicated by the arrows in FIG. 7B, to gently force the contact edge or lip 22 of imaging hood against the tissue T. The positioning of the tissue engaging device 84 may be locked temporarily relative to the deployment catheter 16 to ensure secure positioning of the imaging hood 12 during a diagnostic or therapeutic procedure within the imaging hood 12. After a procedure, tissue engaging device 84 may be disengaged from the tissue by torquing its proximal end in the opposite direction to remove the anchor form the tissue T and the deployment catheter 16 may be repositioned to another region of tissue where the anchoring process may be repeated or removed from the patient body. The tissue engaging device 84 may also be constructed from other known tissue engaging devices such as vacuum-assisted engagement or grasper-assisted engagement tools, among others.

Although a helical anchor 84 is shown, this is intended to be illustrative and other types of temporary anchors may be utilized. e.g., hooked or barbed anchors, graspers, etc. Moreover, the tool delivery catheter 82 may be omitted entirely and the anchoring device may be delivered directly through a lumen defined through the deployment catheter 16.

In another variation where the tool delivery catheter 82 may be omitted entirely to temporarily anchor imaging hood 12, FIG. 7C shows an imaging hood 12 having one or more tubular support members 86, e.g., four support members 86 as shown, integrated with the imaging hood 12. The tubular support members 86 may define lumens therethrough each having helical tissue engaging devices 88 positioned within. When an expanded imaging hood 12 is to be temporarily anchored to the tissue, the helical tissue engaging devices 88 may be urged distally to extend from imaging hood 12 and each may be torqued from its proximal end to engage the underlying tissue T. Each of the helical tissue engaging devices 88 may be advanced through the length of deployment catheter 16 or they may be positioned within tubular support members 86 during the delivery and deployment of imaging hood 12. Once the procedure within imaging hood 12 is finished, each of the tissue engaging devices 88 may be disengaged from the tissue and the imaging hood 12 may be repositioned to another region of tissue or removed from the patient body.

An illustrative example is shown in FIG. 8A of a tissue imaging assembly connected to a fluid delivery system 90 and to an optional processor 98 and image recorder and/or viewer 100. The fluid delivery system 90 may generally comprise a pump 92 and an optional valve 94 for controlling the flow rate of the fluid into the system. A fluid reservoir 96, fluidly connected to pump 92, may hold the fluid to be pumped through imaging hood 12. An optional central processing unit or processor 98 may be in electrical communication with fluid delivery system 90 for controlling flow parameters such as the flow rate and/or velocity of the pumped fluid. The processor 98 may also be in electrical communication with an image recorder and/or viewer 100 for directly viewing the images of tissue received from within imaging hood 12. Imager recorder and/or viewer 100 may also be used not only to record the image but also the location of the viewed tissue region, if so desired.

Optionally, processor 98 may also be utilized to coordinate the fluid flow and the image capture. For instance, processor 98 may be programmed to provide for fluid flow from reservoir 96 until the tissue area has been displaced of blood to obtain a clear image. Once the image has been determined to be sufficiently clear, either visually by a practitioner or by computer, an image of the tissue may be captured automatically by recorder 100 and pump 92 may be automatically stopped or slowed by processor 98 to cease the fluid flow into the patient. Other variations for fluid delivery and image capture are, of course, possible and the aforementioned configuration is intended only to be illustrative and not limiting.

FIG. 8B shows a further illustration of a hand-held variation of the fluid delivery and tissue manipulation system 110. In this variation, system 110 may have a housing or handle assembly 112 which can be held or manipulated by the physician from outside the patient body. The fluid reservoir 114, shown in this variation as a syringe, can be fluidly coupled to the handle assembly 112 and actuated via a pumping mechanism 116, e.g., lead screw. Fluid reservoir 114 may be a simple reservoir separated from the handle assembly 112 and fluidly coupled to handle assembly 112 via one or more tubes. The fluid flow rate and other mechanisms may be metered by the electronic controller 118.

Deployment of imaging hood 12 may be actuated by a hood deployment switch 120 located on the handle assembly 112 while dispensation of the fluid from reservoir 114 may be actuated by a fluid deployment switch 122, which can be electrically coupled to the controller 118. Controller 118 may also be electrically coupled to a wired or wireless antenna 124 optionally integrated with the handle assembly 112, as shown in the figure. The wireless antenna 124 can be used to wirelessly transmit images captured from the imaging hood 12 to a receiver, e.g., via Bluetooth® wireless technology (Bluetooth SIG. Inc., Bellevue, Wash.), RF, etc., for viewing on a monitor 128 or for recording for later viewing.

Articulation control of the deployment catheter 16, or a delivery catheter or sheath 14 through which the deployment catheter 16 may be delivered, may be accomplished by computer control, as described above, in which case an additional controller may be utilized with handle assembly 112. In the case of manual articulation, handle assembly 112 may incorporate one or more articulation controls 126 for manual manipulation of the position of deployment catheter 16. Handle assembly 112 may also define one or more instrument ports 130 through which a number of intravascular tools may be passed for tissue manipulation and treatment within imaging hood 12, as described further below. Furthermore, in certain procedures, fluid or debris may be sucked into imaging hood 12 for evacuation from the patient body by optionally fluidly coupling a suction pump 132 to handle assembly 112 or directly to deployment catheter 16.

As described above, fluid may be pumped continuously into imaging hood 12 to provide for clear viewing of the underlying tissue. Alternatively, fluid may be pumped temporarily or sporadically only until a clear view of the tissue is available to be imaged and recorded, at which point the fluid flow may cease and the blood may be allowed to seep or flow back into imaging hood 12. FIGS. 9A to 9C illustrate an example of capturing several images of the tissue at multiple regions. Deployment catheter 16 may be desirably positioned and imaging hood 12 deployed and brought into position against a region of tissue to be imaged, in this example the tissue surrounding a mitral valve MV within the left atrium of a patient's heart. The imaging hood 12 may be optionally anchored to the tissue, as described above, and then cleared by pumping the imaging fluid into the hood 12. Once sufficiently clear, the tissue may be visualized and the image captured by control electronics 118. The first captured image 140 may be stored and/or transmitted wirelessly 124 to a monitor 128 for viewing by the physician, as shown in FIG. 9A.

The deployment catheter 16 may be then repositioned to an adjacent portion of mitral valve MV, as shown in FIG. 9B, where the process may be repeated to capture a second image 142 for viewing and/or recording. The deployment catheter 16 may again be repositioned to another region of tissue, as shown in FIG. 9C, where a third image 144 may be captured for viewing and/or recording. This procedure may be repeated as many times as necessary for capturing a comprehensive image of the tissue surrounding mitral valve MV, or any other tissue region. When the deployment catheter 16 and imaging hood 12 is repositioned from tissue region to tissue region, the pump may be stopped during positioning and blood or surrounding fluid may be allowed to enter within imaging hood 12 until the tissue is to be imaged, where the imaging hood 12 may be cleared, as above.

As mentioned above, when the imaging hood 12 is cleared by pumping the imaging fluid within for clearing the blood or other bodily fluid, the fluid may be pumped continuously to maintain the imaging fluid within the hood 12 at a positive pressure or it may be pumped under computer control for slowing or stopping the fluid flow into the hood 12 upon detection of various parameters or until a clear image of the underlying tissue is obtained. The control electronics 118 may also be programmed to coordinate the fluid flow into the imaging hood 12 with various physical parameters to maintain a clear image within imaging hood 12.

One example is shown in FIG. 10A which shows a chart 150 illustrating how fluid pressure within the imaging hood 12 may be coordinated with the surrounding blood pressure. Chart 150 shows the cyclical blood pressure 156 alternating between diastolic pressure 152 and systolic pressure 154 over time T due to the beating motion of the patient heart. The fluid pressure of the imaging fluid, indicated by plot 160, within imaging hood 12 may be automatically timed to correspond to the blood pressure changes 160 such that an increased pressure is maintained within imaging hood 12 which is consistently above the blood pressure 156 by a slight increase ΔP, as illustrated by the pressure difference at the peak systolic pressure 158. This pressure difference, ΔP, may be maintained within imaging hood 12 over the pressure variance of the surrounding blood pressure to maintain a positive imaging fluid pressure within imaging hood 12 to maintain a clear view of the underlying tissue. One benefit of maintaining a constant ΔP is a constant flow and maintenance of a clear field.

FIG. 10B shows a chart 162 illustrating another variation for maintaining a clear view of the underlying tissue where one or more sensors within the imaging hood 12, as described in further detail below, may be configured to sense pressure changes within the imaging hood 12 and to correspondingly increase the imaging fluid pressure within imaging hood 12. This may result in a time delay, ΔT, as illustrated by the shifted fluid pressure 160 relative to the cycling blood pressure 156, although the time delays ΔT may be negligible in maintaining the clear image of the underlying tissue. Predictive software algorithms can also be used to substantially eliminate this time delay by predicting when the next pressure wave peak will arrive and by increasing the pressure ahead of the pressure wave's arrival by an amount of time equal to the aforementioned time delay to essentially cancel the time delay out.

The variations in fluid pressure within imaging hood 12 may be accomplished in part due to the nature of imaging hood 12. An inflatable balloon, which is conventionally utilized for imaging tissue, may be affected by the surrounding blood pressure changes. On the other hand, an imaging hood 12 retains a constant volume therewithin and is structurally unaffected by the surrounding blood pressure changes, thus allowing for pressure increases therewithin. The material that hood 12 is made from may also contribute to the manner in which the pressure is modulated within this hood 12. A stiffer hood material, such as high durometer polyurethane or Nylon, may facilitate the maintaining of an open hood when deployed. On the other hand, a relatively lower durometer or softer material, such as a low durometer PVC or polyurethane, may collapse from the surrounding fluid pressure and may not adequately maintain a deployed or expanded hood.

Turning now to the imaging hood, other variations of the tissue imaging assembly may be utilized, as shown in FIG. 11A, which shows another variation comprising an additional imaging balloon 172 within an imaging hood 174. In this variation, an expandable balloon 172 having a translucent skin may be positioned within imaging hood 174. Balloon 172 may be made from any distensible biocompatible material having sufficient translucent properties which allow for visualization therethrough. Once the imaging hood 174 has been deployed against the tissue region of interest, balloon 172 may be filled with a fluid, such as saline, or less preferably a gas, until balloon 172 has been expanded until the blood has been sufficiently displaced. The balloon 172 may thus be expanded proximal to or into contact against the tissue region to be viewed. The balloon 172 can also be filled with contrast media to allow it to be viewed on fluoroscopy to aid in its positioning. The imager, e.g., fiber optic, positioned within deployment catheter 170 may then be utilized to view the tissue region through the balloon 172 and any additional fluid which may be pumped into imaging hood 174 via one or more optional fluid ports 176, which may be positioned proximally of balloon 172 along a portion of deployment catheter 170. Alternatively, balloon 172 may define one or more holes over its surface which allow for seepage or passage of the fluid contained therein to escape and displace the blood from within imaging hood 174.

FIG. 11B shows another alternative in which balloon 180 may be utilized alone. Balloon 180, attached to deployment catheter 178, may be filled with fluid, such as saline or contrast media, and is preferably allowed to come into direct contact with the tissue region to be imaged.

FIG. 12A shows another alternative in which deployment catheter 16 incorporates imaging hood 12, as above, and includes an additional flexible membrane 182 within imaging hood 12. Flexible membrane 182 may be attached at a distal end of catheter 16 and optionally at contact edge 22. Imaging hood 12 may be utilized, as above, and membrane 182 may be deployed from catheter 16 in vivo or prior to placing catheter 16 within a patient to reduce the volume within imaging hood 12. The volume may be reduced or minimized to reduce the amount of fluid dispensed for visualization or simply reduced depending upon the area of tissue to be visualized.

FIGS. 12B and 12C show yet another alternative in which imaging hood 186 may be withdrawn proximally within deployment catheter 184 or deployed distally from catheter 186, as shown, to vary the volume of imaging hood 186 and thus the volume of dispensed fluid. Imaging hood 186 may be seen in FIG. 12B as being partially deployed from, e.g., a circumferentially defined lumen within catheter 184, such as annular lumen 188. The underlying tissue may be visualized with imaging hood 186 only partially deployed. Alternatively, imaging hood 186′ may be fully deployed, as shown in FIG. 12C, by urging hood 186′ distally out from annular lumen 188. In this expanded configuration, the area of tissue to be visualized may be increased as hood 186′ is expanded circumferentially.

FIGS. 13A and 13B show perspective and cross-sectional side views, respectively, of yet another variation of imaging assembly which may utilize a fluid suction system for minimizing the amount of fluid injected into the patient's heart or other body lumen during tissue visualization. Deployment catheter 190 in this variation may define an inner tubular member 196 which may be integrated with deployment catheter 190 or independently translatable. Fluid delivery lumen 198 defined through member 196 may be fluidly connected to imaging hood 192, which may also define one or more open channels 194 over its contact lip region. Fluid pumped through fluid delivery lumen 198 may thus fill open area 202 to displace any blood or other fluids or objects therewithin. As the clear fluid is forced out of open area 202, it may be sucked or drawn immediately through one or more channels 194 and back into deployment catheter 190. Tubular member 196 may also define one or more additional working channels 200 for the passage of any tools or visualization devices.

In deploying the imaging hood in the examples described herein, the imaging hood may take on any number of configurations when positioned or configured for a low-profile delivery within the delivery catheter, as shown in the examples of FIGS. 14A to 14D. These examples are intended to be illustrative and are not intended to be limiting in scope. FIG. 14A shows one example in which imaging hood 212 may be compressed within catheter 210 by folding hood 212 along a plurality of pleats. Hood 212 may also comprise scaffolding or frame 214 made of a super-elastic or shape memory material or alloy, e.g., Nitinol, Elgiloy, shape memory polymers, electroactive polymers, or a spring stainless steel. The shape memory material may act to expand or deploy imaging hood 212 into its expanded configuration when urged in the direction of the arrow from the constraints of catheter 210.

FIG. 14B shows another example in which imaging hood 216 may be expanded or deployed from catheter 210 from a folded and overlapping configuration. Frame or scaffolding 214 may also be utilized in this example. FIG. 14C shows yet another example in which imaging hood 218 may be rolled, inverted, or evened upon itself for deployment. In yet another example, FIG. 14D shows a configuration in which imaging hood 220 may be fabricated from an extremely compliant material which allows for hood 220 to be simply compressed into a low-profile shape. From this low-profile compressed shape, simply releasing hood 220 may allow for it to expand into its deployed configuration, especially if a scaffold or frame of a shape memory or superelastic material, e.g., Nitinol, is utilized in its construction.

Another variation for expanding the imaging hood is shown in FIGS. 15A and 15B which illustrates an helically expanding frame or support 230. In its constrained low-profile configuration, shown in FIG. 15A, helical frame 230 may be integrated with the imaging hood 12 membrane. When free to expand, as shown in FIG. 15B, helical frame 230 may expand into a conical or tapered shape. Helical frame 230 may alternatively be made out of heat-activated Nitinol to allow it to expand upon application of a current.

FIGS. 16A and 16B show yet another variation in which imaging hood 12 may comprise one or more hood support members 232 integrated with the hood membrane. These longitudinally attached support members 232 may be pivotably attached at their proximal ends to deployment catheter 16. One or more pullwires 234 may be routed through the length of deployment catheter 16 and extend through one or more openings 238 defined in deployment catheter 16 proximally to imaging hood 12 into attachment with a corresponding support member 232 at a pullwire attachment point 236. The support members 232 may be fabricated from a plastic or metal, such as stainless steel. Alternatively, the support members 232 may be made from a superelastic or shape memory alloy, such as Nitinol, which may self-expand into its deployed configuration without the use or need of pullwires. A heat-activated Nitinol may also be used which expands upon the application of thermal energy or electrical energy. In another alternative, support members 232 may also be constructed as inflatable lumens utilizing, e.g., PET balloons. From its low-profile delivery configuration shown in FIG. 16A, the one or more pullwires 234 may be tensioned from their proximal ends outside the patient body to pull a corresponding support member 232 into a deployed configuration, as shown in FIG. 16B, to expand imaging hood 12. To reconfigure imaging hood 12 back into its low profile, deployment catheter 16 may be pulled proximally into a constraining catheter or the pullwires 234 may be simply pushed distally to collapse imaging hood 12.

FIGS. 17A and 17B show yet another variation of imaging hood 240 having at least two or more longitudinally positioned support members 242 supporting the imaging hood membrane. The support members 242 each have cross-support members 244 which extend diagonally between and are pivotably attached to the support members 242. Each of the cross-support members 244 may be pivotably attached to one another where they intersect between the support members 242. A jack or screw member 246 may be coupled to each cross-support member 244 at this intersection point and a torquing member, such as a torqueable wire 248, may be coupled to each jack or screw member 246 and extend proximally through deployment catheter 16 to outside the patient body. From outside the patient body, the torqueable wires 248 may be torqued to turn the jack or screw member 246 which in turn urges the cross-support members 244 to angle relative to one another and thereby urge the support members 242 away from one another. Thus, the imaging hood 240 may be transitioned from its low-profile, shown in FIG. 17A, to its expanded profile, shown in FIG. 178, and back into its low-profile by torquing wires 248.

FIGS. 18A and 18B show yet another variation on the imaging hood and its deployment. As shown, a distal portion of deployment catheter 16 may have several pivoting members 250, e.g., two to four sections, which form a tubular shape in its low profile configuration, as shown in FIG. 18A. When pivoted radially about deployment catheter 16, pivoting members 250 may open into a deployed configuration having distensible or expanding membranes 252 extending over the gaps in-between the pivoting members 250, as shown in FIG. 18B. The distensible membrane 252 may be attached to the pivoting members 250 through various methods, e.g., adhesives, such that when the pivoting members 250 are fully extended-into a conical shape, the pivoting members 250 and membrane 252 form a conical shape for use as an imaging hood. The distensible membrane 252 may be made out of a porous material such as a mesh or PTFE or out of a translucent or transparent polymer such as polyurethane, PVC, Nylon, etc.

FIGS. 19A and 19B show yet another variation where the distal portion of deployment catheter 16 may be fabricated from a flexible metallic or polymeric material to form a radially expanding hood 254. A plurality of slots 256 may be formed in a uniform pattern over the distal portion of deployment catheter 16, as shown in FIG. 19A. The slots 256 may be formed in a pattern such that when the distal portion is urged radially open, utilizing any of the methods described above, a radially expanded and conically-shaped hood 254 may be formed by each of the slots 256 expanding into an opening, as shown in FIG. 19B. A distensible membrane 258 may overlie the exterior surface or the interior surface of the hood 254 to form a fluid-impermeable hood 254 such that the hood 254 may be utilized as an imaging hood. Alternatively, the distensible membrane 258 may alternatively be formed in each opening 258 to form the fluid-impermeable hood 254. Once the imaging procedure has been completed, hood 254 may be retracted into its low-profile configuration.

Yet another configuration for the imaging hood may be seen in FIGS. 20A and 20B where the imaging hood may be formed from a plurality of overlapping hood members 260 which overlie one another in an overlapping pattern. When expanded, each of the hood members 260 may extend radially outward relative to deployment catheter 16 to form a conically-shaped imaging hood, as shown in FIG. 20B. Adjacent hood members 260 may overlap one another along an overlapping interface 262 to form a fluid-retaining surface within the imaging hood. Moreover, the hood members 260 may be made from any number of biocompatible materials, e.g., Nitinol, stainless steel, polymers, etc., which are sufficiently strong to optionally retract surrounding tissue from the tissue region of interest.

Although it is generally desirable to have an imaging hood contact against a tissue surface in a normal orientation, the imaging hood may be alternatively configured to contact the tissue surface at an acute angle. An imaging hood configured for such contact against tissue may also be especially suitable for contact against tissue surfaces having an unpredictable or uneven anatomical geography. For instance, as shown in the variation of FIG. 21A, deployment catheter 270 may have an imaging hood 272 that is configured to be especially compliant. In this variation, imaging hood 272 may be comprised of one or more sections 274 that are configured to fold or collapse, e.g., by utilizing a pleated surface. Thus, as shown in FIG. 21B, when imaging hood 272 is contacted against uneven tissue surface T, sections 274 are able to conform closely against the tissue. These sections 274 may be individually collapsible by utilizing an accordion style construction to allow conformation, e.g., to the trabeculae in the heart or the uneven anatomy that may be found inside the various body lumens.

In yet another alternative, FIG. 22A shows another variation in which an imaging hood 282 is attached to deployment catheter 280. The contact lip or edge 284 may comprise one or more electrical contacts 286 positioned circumferentially around contact edge 284. The electrical contacts 286 may be configured to contact the tissue and indicate affirmatively whether tissue contact was achieved, e.g., by measuring the differential impedance between blood and tissue. Alternatively, a processor, e.g., processor 98, in electrical communication with contacts 286 may be configured to determine what type of tissue is in contact with electrical contacts 286. In yet another alternative, the processor 98 may be configured to measure any electrical activity that may be occurring in the underlying tissue, e.g., accessory pathways, for the purposes of electrically mapping the cardiac tissue and subsequently treating, as described below, any arrhythmias which may be detected.

Another variation for ensuring contact between imaging hood 282 and the underlying tissue may be seen in FIG. 22B. This variation may have an inflatable contact edge 288 around the circumference of imaging hood 282. The inflatable contact edge 288 may be inflated with a fluid or gas through inflation lumen 289 when the imaging hood 282 is to be placed against a tissue surface having an uneven or varied anatomy. The inflated circumferential surface 288 may provide for continuous contact over the hood edge by conforming against the tissue surface and facilitating imaging fluid retention within hood 282.

Aside from the imaging hood, various instrumentation may be utilized with the imaging and manipulation system. For instance, after the field within imaging hood 12 has been cleared of the opaque blood and the underlying tissue is visualized through the clear fluid, blood may seep back into the imaging hood 12 and obstruct the view. One method for automatically maintaining a clear imaging field may utilize a transducer. e.g., an ultrasonic transducer 290, positioned at the distal end of deployment catheter within the imaging hood 12, as shown in FIG. 23. The transducer 290 may send an energy pulse 292 into the imaging hood 12 and wait to detect back-scattered energy 294 reflected from debris or blood within the imaging hood 12. If back-scattered energy is detected, the pump may be actuated automatically to dispense more fluid into the imaging hood until the debris or blood is no longer detected.

Alternatively, one or more sensors 300 may be positioned on the imaging hood 12 itself, as shown in FIG. 24A, to detect a number of different parameters. For example, sensors 300 may be configured to detect for the presence of oxygen in the surrounding blood, blood and/or imaging fluid pressure, color of the fluid within the imaging hood, etc. Fluid color may be particularly useful in detecting the presence of blood within the imaging hood 12 by utilizing a reflective type sensor to detect back reflection from blood. Any reflected light from blood which may be present within imaging hood 12 may be optically or electrically transmitted through deployment catheter 16 and to a red colored filter within control electronics 118. Any red color which may be detected may indicate the presence of blood and trigger a signal to the physician or automatically actuate the pump to dispense more fluid into the imaging hood 12 to clear the blood.

Alternative methods for detecting the presence of blood within the hood 12 may include detecting transmitted light through the imaging fluid within imaging hood 12. If a source of white light, e.g., utilizing LEDs or optical fibers, is illuminated inside imaging hood 12, the presence of blood may cause the color red to be filtered through this fluid. The degree or intensity of the red color detected may correspond to the amount of blood present within imaging hood 12. A red color sensor can simply comprise, in one variation, a phototransistor with a red transmitting filter over it which can establish how much red light is detected, which in turn can indicate the presence of blood within imaging hood 12. Once blood is detected, the system may pump more clearing fluid through and enable closed loop feedback control of the clearing fluid pressure and flow level.

Any number of sensors may be positioned along the exterior 302 of imaging hood 12 or within the interior 304 of imaging hood 12 to detect parameters not only exteriorly to imaging hood 12 but also within imaging hood 12. Such a configuration, as shown in FIG. 24B, may be particularly useful for automatically maintaining a clear imaging field based upon physical parameters such as blood pressure, as described above for FIGS. 10A and 10B.

Aside from sensors, one or more light emitting diodes (LEDs) may be utilized to provide lighting within the imaging hood 12. Although illumination may be provided by optical fibers routed through deployment catheter 16, the use of LEDs over the imaging hood 12 may eliminate the need for additional optical fibers for providing illumination. The electrical wires connected to the one or more LEDs may be routed through or over the hood 12 and along an exterior surface or extruded within deployment catheter 16. One or more LEDs may be positioned in a circumferential pattern 306 around imaging hood 12, as shown in FIG. 25A, or in a linear longitudinal pattern 308 along imaging hood 12, as shown in FIG. 25B. Other patterns, such as a helical or spiral pattern, may also be utilized. Alternatively, LEDs may be positioned along a support member forming part of imaging hood 12.

In another alternative for illumination within imaging hood 12, a separate illumination tool 310 may be utilized, as shown in FIG. 26A. An example of such a tool may comprise a flexible intravascular delivery member 312 having a carrier member 314 pivotably connected 316 to a distal end of delivery member 312. One or more LEDs 318 may be mounted along carrier member 314. In use, delivery member 312 may be advanced through deployment catheter 16 until carrier member 314 is positioned within imaging hood 12. Once within imaging hood 12, carrier member 314 may be pivoted in any number of directions to facilitate or optimize the illumination within the imaging hood 12, as shown in FIG. 26B.

In utilizing LEDs for illumination, whether positioned along imaging hood 12 or along a separate instrument, the LEDs may comprise a single LED color, e.g., white light. Alternatively, LEDs of other colors, e.g., red, blue, yellow, etc., may be utilized exclusively or in combination with white LEDs to provide for varied illumination of the tissue or fluids being imaged. Alternatively, sources of infrared or ultraviolet light may be employed to enable imaging beneath the tissue surface or cause fluorescence of tissue for use in system guidance, diagnosis, or therapy.

Aside from providing a visualization platform, the imaging assembly may also be utilized to provide a therapeutic platform for treating tissue being visualized. As shown in FIG. 27, deployment catheter 320 may have imaging hood 322, as described above, and fluid delivery lumen 324 and imaging lumen 326. In this variation, a therapeutic tool such as needle 328 may be delivered through fluid delivery lumen 324 or in another working lumen and advanced through open area 332 for treating the tissue which is visualized. In this instance, needle 328 may define one or several ports 330 for delivering drugs therethrough. Thus, once the appropriate region of tissue has been imaged and located, needle 328 may be advanced and pierced into the underlying tissue where a therapeutic agent may be delivered through ports 330. Alternatively, needle 328 may be in electrical communication with a power source 334, e.g., radio-frequency, microwave, etc., for ablating the underlying tissue area of interest.

FIG. 28 shows another alternative in which deployment catheter 340 may have imaging hood 342 attached thereto, as above, but with a therapeutic tool 344 in the configuration of a helical tissue piercing device 344. Also shown and described above in FIGS. 7A and 7B for use in stabilizing the imaging hood relative to the underlying tissue, the helical tissue piercing device 344 may also be utilized to manipulate the tissue for a variety of therapeutic procedures. The helical portion 346 may also define one or several ports for delivery of therapeutic agents therethrough.

In yet another alternative, FIG. 29 shows a deployment catheter 350 having an expandable imaging balloon 352 filled with, e.g., saline 356. A therapeutic tool 344, as above, may be translatable relative to balloon 352. To prevent the piercing portion 346 of the tool from tearing balloon 352, a stop 354 may be formed on balloon 352 to prevent the proximal passage of portion 346 past stop 354.

Alternative configurations for tools which may be delivered through deployment catheter 16 for use in tissue manipulation within imaging hood 12 are shown in FIGS. 30A and 30B. FIG. 30A shows one variation of an angled instrument 360, such as a tissue grasper, which may be configured to have an elongate shaft for intravascular delivery through deployment catheter 16 with a distal end which may be angled relative to its elongate shaft upon deployment into imaging hood 12. The elongate shaft may be configured to angle itself automatically, e.g., by the elongate shaft being made at least partially from a shape memory alloy, or upon actuation, e.g., by tensioning a pullwire. FIG. 30B shows another configuration for an instrument 362 being configured to reconfigure its distal portion into an off-axis configuration within imaging hood 12. In either case, the instruments 360, 362 may be reconfigured into a low-profile shape upon withdrawing them proximally back into deployment catheter 16.

Other instruments or tools which may be utilized with the imaging system is shown in the side and end views of FIGS. 31A to 31C. FIG. 31 IA shows a probe 370 having a distal end effector 372, which may be reconfigured from a low-profile shape to a curved profile. The end effector 372 may be configured as an ablation probe utilizing radio-frequency energy, microwave energy, ultrasound energy, laser energy or even cryo-ablation. Alternatively, the end effector 372 may have several electrodes upon it for detecting or mapping electrical signals transmitted through the underlying tissue.

In the case of an end effector 372 utilized for ablation of the underlying tissue, an additional temperature sensor such as a thermocouple or thermistor 374 positioned upon an elongate member 376 may be advanced into the imaging hood 12 adjacent to the distal end effector 372 for contacting and monitoring a temperature of the ablated tissue. FIG. 31B shows an example in the end view of one configuration for the distal end effector 372 which may be simply angled into a perpendicular configuration for contacting the tissue. FIG. 31C shows another example where the end effector may be reconfigured into a curved end effector 378 for increased tissue contact.

FIGS. 32A and 32B show another variation of an ablation tool utilized with an imaging hood 12 having an enclosed bottom portion. In this variation, an ablation probe, such as a cryo-ablation probe 380 having a distal end effector 382, may be positioned through the imaging hood 12 such that the end effector 382 is placed distally of a transparent membrane or enclosure 384, as shown in the end view of FIG. 32B. The shaft of probe 380 may pass through an opening 386 defined through the membrane 384. In use, the clear fluid may be pumped into imaging hood 12, as described above, and the distal end effector 382 may be placed against a tissue region to be ablated with the imaging hood 12 and the membrane 384 positioned atop or adjacent to the ablated tissue. In the case of cryo-ablation, the imaging fluid may be warmed prior to dispensing into the imaging hood 12 such that the tissue contacted by the membrane 384 may be warmed during the cryo-ablation procedure. In the case of thermal ablation, e.g., utilizing radio-frequency energy, the fluid dispensed into the imaging hood 12 may be cooled such that the tissue contacted by the membrane 384 and adjacent to the ablation probe during the ablation procedure is likewise cooled.

In either example described above, the imaging fluid may be varied in its temperature to facilitate various procedures to be performed upon the tissue. In other cases, the imaging fluid itself may be altered to facilitate various procedures. For instance as shown in FIG. 33A, a deployment catheter 16 and imaging hood 12 may be advanced within a hollow body organ, such as a bladder filled with urine 394, towards a lesion or tumor 392 on the bladder wall. The imaging hood 12 may be placed entirely over the lesion 392, or over a portion of the lesion. Once secured against the tissue wall 390, a cryo-fluid, i.e., a fluid which has been cooled to below freezing temperatures of, e.g., water or blood, may be pumped into the imaging hood 12 to cryo-ablate the lesion 390, as shown in FIG. 33B while avoiding the creation of ice on the instrument or surface of tissue.

As the cryo-fluid leaks out of the imaging hood 12 and into the organ, the fluid may be warmed naturally by the patient body and ultimately removed. The cryo-fluid may be a colorless and translucent fluid which enables visualization therethrough of the underlying tissue. An example of such a fluid is Fluorinert™ (3M, St. Paul, Minn.), which is a colorless and odorless perfluorinated liquid. The use of a liquid such as Fluorinert™ enables the cryo-ablation procedure without the formation of ice within or outside of the imaging hood 12. Alternatively, rather than utilizing cryo-ablation, hyperthermic treatments may also be effected by heating the Fluorinert™ liquid to elevated temperatures for ablating the lesion 392 within the imaging hood 12. Moreover, Fluorinert™ may be utilized in various other parts of the body, such as within the heart.

FIG. 34A shows another variation of an instrument which may be utilized with the imaging system. In this variation, a laser ring generator 400 may be passed through the deployment catheter 16 and partially into imaging hood 12. A laser ring generator 400 is typically used to create a circular ring of laser energy 402 for generating a conduction block around the pulmonary veins typically in the treatment of atrial fibrillation. The circular ring of laser energy 402 may be generated such that a diameter of the ring 402 is contained within a diameter of the imaging hood 12 to allow for tissue ablation directly upon tissue being imaged. Signals which cause atrial fibrillation typically come from the entry area of the pulmonary veins into the left atrium and treatments may sometimes include delivering ablation energy to the ostia of the pulmonary veins within the atrium. The ablated areas of the tissue may produce a circular scar which blocks the impulses for atrial fibrillation.

When using the laser energy to ablate the tissue of the heart, it may be generally desirable to maintain the integrity and health of the tissue overlying the surface while ablating the underlying tissue. This may be accomplished, for example, by cooling the imaging fluid to a temperature below the body temperature of the patient but which is above the freezing point of blood (e.g., 2° C. to 35° C.). The cooled imaging fluid may thus maintain the surface tissue at the cooled fluid temperature while the deeper underlying tissue remains at the patient body temperature. When the laser energy (or other types of energy such as radio frequency energy, microwave energy, ultrasound energy, etc.) irradiates the tissue, both the cooled tissue surface as well as the deeper underlying tissue will rise in temperature uniformly. The deeper underlying tissue, which was maintained at the body temperature, will increase to temperatures which are sufficiently high to destroy the underlying tissue. Meanwhile, the temperature of the cooled surface tissue will also rise but only to temperatures that are near body temperature or slightly above.

Accordingly, as shown in FIG. 34B, one example for treatment may include passing deployment catheter 16 across the atrial septum AS and into the left atrium LA of the patient's heart H. Other methods of accessing the left atrium LA may also be utilized. The imaging hood 12 and laser ring generator 400 may be positioned adjacent to or over one or more of the ostium OT of the pulmonary veins PV and the laser generator 400 may ablate the tissue around the ostium OT with the circular ring of laser energy 402 to create a conduction block. Once one or more of the tissue around the ostium OT have been ablated, the imaging hood 12 may be reconfigured into a low profile for removal from the patient heart H.

One of the difficulties in treating tissue in or around the ostium OT is the dynamic fluid flow of blood through the ostium OT. The dynamic forces make cannulation or entry of the ostium OT difficult. Thus, another variation on instruments or tools utilizable with the imaging system is an extendible cannula 410 having a cannula lumen 412 defined therethrough, as shown in FIG. 35A. The extendible cannula 410 may generally comprise an elongate tubular member which may be positioned within the deployment catheter 16 during delivery and then projected distally through the imaging hood 12 and optionally beyond, as shown in FIG. 35B.

In use, once the imaging hood 12 has been desirably positioned relative to the tissue, e.g., as shown in FIG. 35C outside the ostium OT of a pulmonary vein PV, the extendible cannula 410 may be projected distally from the deployment catheter 16 while optionally imaging the tissue through the imaging hood 12, as described above. The extendible cannula 410 may be projected distally until its distal end is extended at least partially into the ostium OT. Once in the ostium OT, an instrument or energy ablation device may be extended through and out of the cannula lumen 412 for treatment within the ostium OT. Upon completion of the procedure, the cannula 410 may be withdrawn proximally and removed from the patient body. The extendible cannula 410 may also include an inflatable occlusion balloon at or near its distal end to block the blood flow out of the PV to maintain a clear view of the tissue region. Alternatively, the extendible cannula 410 may define a lumen therethrough beyond the occlusion balloon to bypass at least a portion of the blood that normally exits the pulmonary vein PV by directing the blood through the cannula 410 to exit proximal of the imaging blood.

Yet another variation for tool or instrument use may be seen in the side and end views of FIGS. 36A and 36B. In this variation, imaging hood 12 may have one or more tubular support members 420 integrated with the hood 12. Each of the tubular support members 420 may define an access lumen 422 through which one or more instruments or tools may be delivered for treatment upon the underlying tissue. One particular example is shown and described above for FIG. 7C.

Various methods and instruments may be utilized for using or facilitating the use of the system. For instance, one method may include facilitating the initial delivery and placement of a device into the patient's heart. In initially guiding the imaging assembly within the heart chamber to, e.g., the mitral valve MV, a separate guiding probe 430 may be utilized, as shown in FIGS. 37A and 37B. Guiding probe 430 may, for example, comprise an optical fiber through which a light source 434 may be used to illuminate a distal tip portion 432. The tip portion 432 may be advanced into the heart through, e.g., the coronary sinus CS, until the tip is positioned adjacent to the mitral valve MV. The tip 432 may be illuminated, as shown in FIG. 37A, and imaging assembly 10 may then be guided towards the illuminated tip 432, which is visible from within the atrial chamber, towards mitral valve MV.

Aside from the devices and methods described above, the imaging system may be utilized to facilitate various other procedures. Turning now to FIGS. 38A and 38B, the imaging hood of the device in particular may be utilized. In this example, a collapsible membrane or disk-shaped member 440 may be temporarily secured around the contact edge or lip of imaging hood 12. During intravascular delivery, the imaging hood 12 and the attached member 440 may both be in a collapsed configuration to maintain a low profile for delivery. Upon deployment, both the imaging hood 12 and the member 440 may extend into their expanded configurations.

The disk-shaped member 440 may be comprised of a variety of materials depending upon the application. For instance, member 440 may be fabricated from a porous polymeric material infused with a drug eluting medicament 442 for implantation against a tissue surface for slow infusion of the medicament into the underlying tissue. Alternatively, the member 440 may be fabricated from a non-porous material, e.g., metal or polymer, for implantation and closure of a wound or over a cavity to prevent fluid leakage. In yet another alternative, the member 440 may be made from a distensible material which is secured to imaging hood 12 in an expanded condition. Once implanted or secured on a tissue surface or wound, the expanded member 440 may be released from imaging hood 12. Upon release, the expanded member 440 may shrink to a smaller size while approximating the attached underlying tissue, e.g., to close a wound or opening.

One method for securing the disk-shaped member 440 to a tissue surface may include a plurality of tissue anchors 444, e.g., barbs, hooks, projections, etc., which are attached to a surface of the member 440. Other methods of attachments may include adhesives, suturing, etc. In use, as shown in FIGS. 39A to 39C, the imaging hood 12 may be deployed in its expanded configuration with member 440 attached thereto with the plurality of tissue anchors 444 projecting distally. The tissue anchors 444 may be urged into a tissue region to be treated 446, as seen in FIG. 39A, until the anchors 444 are secured in the tissue and member 440 is positioned directly against the tissue, as shown in FIG. 39B. A pullwire may be actuated to release the member 440 from the imaging hood 12 and deployment catheter 16 may be withdrawn proximally to leave member 440 secured against the tissue 446.

Another variation for tissue manipulation and treatment may be seen in the variation of FIG. 40A, which illustrates an imaging hood 12 having a deployable anchor assembly 450 attached to the tissue contact edge 22. FIG. 40B illustrates the anchor assembly 450 detached from the imaging hood 12 for clarity. The anchor assembly 450 may be seen as having a plurality of discrete tissue anchors 456, e.g., barbs, hooks, projections, etc., each having a suture retaining end, e.g., an eyelet or opening 458 in a proximal end of the anchors 456. A suture member or wire 452 may be slidingly connected to each anchor 456 through the openings 458 and through a cinching element 454, which may be configured to slide uni-directionally over the suture or wire 452 to approximate each of the anchors 456 towards one another. Each of the anchors 456 may be temporarily attached to the imaging hood 12 through a variety of methods. For instance, a pullwire or retaining wire may hold each of the anchors within a receiving ring around the circumference of the imaging hood 12. When the anchors 456 are released, the pullwire or retaining wire may be tensioned from its proximal end outside the patient body to thereby free the anchors 456 from the imaging hood 12.

One example for use of the anchor assembly 450 is shown in FIGS. 41A to 41D for closure of an opening or wound 460, e.g., patent foramen ovale (PFO). The deployment catheter 16 and imaging hood 12 may be delivered intravascularly into, e.g., a patient heart. As the imaging hood 12 is deployed into its expanded configuration, the imaging hood 12 may be positioned adjacent to the opening or wound 460, as shown in FIG. 41A. With the anchor assembly 450 positioned upon the expanded imaging hood 12, deployment catheter 16 may be directed to urge the contact edge of imaging hood 12 and anchor assembly 450 into the region surrounding the tissue opening 460, as shown in FIG. 41B. Once the anchor assembly 450 has been secured within the surrounding tissue, the anchors may be released from imaging hood 12 leaving the anchor assembly 450 and suture member 452 trailing from the anchors, as shown in FIG. 41C. The suture or wire member 452 may be tightened by pulling it proximally from outside the patient body to approximate the anchors of anchor assembly 450 towards one another in a purse-string manner to close the tissue opening 462, as shown in FIG. 41D. The cinching element 454 may also be pushed distally over the suture or wire member 452 to prevent the approximated anchor assembly 450 from loosening or widening.

Another example for an alternative use is shown in FIG. 42, where the deployment catheter 16 and deployed imaging hood 12 may be positioned within a patient body for drawing blood 472 into deployment catheter 16. The drawn blood 472 may be pumped through a dialysis unit 470 located externally of the patient body for filtering the drawn blood 472 and the filtered blood may be reintroduced back into the patient.

Yet another variation is shown in FIGS. 43A and 43B, which show a variation of the deployment catheter 480 having a first deployable hood 482 and a second deployable hood 484 positioned distal to the first hood 482. The deployment catheter 480 may also have a side-viewing imaging element 486 positioned between the first and second hoods 482, 484 along the length of the deployment catheter 480. In use, such a device may be introduced through a lumen 488 of a vessel VS, where one or both hoods 482, 484 may be expanded to gently contact the surrounding walls of vessel VS. Once hoods 482, 484 have been expanded, the clear imaging fluid may be pumped in the space defined between the hoods 482, 484 to displace any blood and to create an imaging space 490, as shown in FIG. 43B. With the clear fluid in-between hoods 482, 484, the imaging element 486 may be used to view the surrounding tissue surface contained between hoods 482, 484. Other instruments or tools may be passed through deployment catheter 480 and through one or more openings defined along the catheter 480 for additionally performing therapeutic procedures upon the vessel wall.

Another variation of a deployment catheter 500 which may be used for imaging tissue to the side of the instrument may be seen in FIGS. 44A to 45B. FIGS. 44A and 44B show side and end views of deployment catheter 500 having a side-imaging balloon 502 in an un-inflated low-profile configuration. A side-imaging element 504 may be positioned within a distal portion of the catheter 500 where the balloon 502 is disposed. When balloon 502 is inflated, it may expand radially to contact the surrounding tissue, but where the imaging element 504 is located, a visualization field 506 may be created by the balloon 502, as shown in the side, top, and end views of FIGS. 45A to 45B, respectively. The visualization field 506 may simply be a cavity or channel which is defined within the inflated balloon 502 such that the visualization element 504 is provided an image of the area within field 506 which is clear and unobstructed by balloon 502.

In use, deployment catheter 500 may be advanced intravascularly through vessel lumen 488 towards a lesion or tumor 508 to be visualized and/or treated. Upon reaching the lesion 508, deployment catheter 500 may be positioned adjacently to the lesion 508 and balloon 502 may be inflated such that the lesion 508 is contained within the visualization field 506. Once balloon 502 is fully inflated and in contact against the vessel wall, clear fluid may be pumped into visualization field 506 through deployment catheter 500 to displace any blood or opaque fluids from the field 506, as shown in the side and end views of FIGS. 46A and 46B, respectively. The lesion 508 may then be visually inspected and treated by passing any number of instruments through deployment catheter 500 and into field 506.

In controlling the advancement and articulation of any of the delivery catheters described herein, the catheter may be manually controlled or robotically-controlled, as mentioned above. Examples of robotically-controlled catheter systems which utilize precision motion control mechanisms are shown and described in U.S. Pat. App. 2006/0084945 A1 and U.S. Pat. No. 7,090,683, each of which is incorporated herein by reference in its entirety. Generally, a visualization hood may be attached or coupled to the distal end of a catheter articulated or controlled by precision motion control mechanisms. The articulatable neck portion of the shaft, located proximally of the visualization hood, may be comprised of an assembly of links fabricated, e.g., from stainless steel, plastics, etc., that allow the neck portion to be articulated in multiple planes. One or more, e.g., four, pullwires may be routed through the neck and/or shaft such that they terminate at the hood attachment, while the proximal end or ends of the pullwires may be routed through the links to a proximal end of the catheter. Combinations of retraction and/or extension motions of these pullwires may be utilized to steer the neck portion to articulate the hood in multiple directions as desired by the operator.

The proximal ends of the pullwires are threaded through a pulley assembly and terminated in rotatable spools. Rotating these spools will either retract the pullwires or release more slack into the catheter to enable steering as appropriate. The pullwire spools are further driven by control elements such as low speed motors, which in turn, may be driven by a central processing unit Precise and consistent low speed rotation of the spools controlled by the central processing unit and the motors will enable the pullwires to be retracted or released with high precision. This will translate into precision articulation and motion control of the tissue visualization hood.

Referring now to FIG. 47A, an example of a robotic guide instrument 600 is illustrated having two control element interface assemblies configured to drive, e.g., four control elements 606, e.g., pullwires. Rotation of the pulleys in a first direction may spool and proximally displace one control element 606, while unspooling in a second opposite direction may distally displace a complementary control element 606 to deflect the distal end of the deployment catheter 14 in the opposite direction. Tension may be maintained in the control elements 606 via pre-tensioning or pre-stressing the elements to prevent excess slack. Tension may also be maintained on the control elements 606 using a slotted guide instrument base 602 which forms one or more slots 604 through which the control elements 606 may remain taut.

FIG. 47B illustrates the robotic guide instrument 600 having hood 12 positioned upon deployment catheter 16 with an inflatable balloon or membrane 608 optionally disposable within or upon hood 12 and an instrument advanced through catheter 16 and into hood 12. As schematically illustrated, the robotic guide instrument 600, and optionally the instruments advanced through hood 12, may be controlled via a computer or processor 612 to control the articulation of the hood 12 as well as other functions. The treatment instrument may include any number of instruments, e.g., ablation tools, a piercing needle 610, etc., which may be advanced through the hood for treating the underlying tissue. Examples of instruments as well as alternative configurations for hood 12 are shown and described in further detail in the following U.S. patent application Ser. Nos. 11/775,771 and 11/775,837 both filed Jul. 10, 2007, and Ser. No. 11/828,267 filed Jul. 25, 2007, each of which is incorporated herein by reference in its entirety.

FIG. 47C illustrates an example of how a robotic guide instrument may be utilized with a visualization system. Generally, a user may interface with input device 651, which may utilize any number of different interfaces, e.g., handle, joystick, etc., by which the user may transmit desired commands to processor 631. Processor 631 may receive the commands and transmit the appropriate drive signals to the catheter and computer-controlled guidance assembly 639 which may then control the hood, imaging systems, fluid purging systems, etc. in accordance with the received commands from the user. When the catheter and/or hood interfaces with the surrounding tissue, the resulting force or tracking feedback may be optionally sensed by guidance assembly 639 and transmitted back to processor 631, which in turn may signal or indicate to the user via force feedback through input device 651 or some other force or visual feedback. Moreover, the image data captured by the imaging element within or along hood 12 may also be received by guidance assembly 639 and transmitted to processor 631, which may receive the image data for processing and display upon a tissue surface image display 649 to the user.

Catheter and computer-controlled guidance assembly 639 may comprise several sub-systems for controlling each of a number of different functions, for instance (amongst other sub-systems), an articulation drive 641 for controlling a movement of the catheter 16 and/or hood 12, a movement tracking system 643 for tracking a position and/or orientation of the catheter 16 and/or hood 12 within the patient body, an imaging element system 645 for controlling the visualization features, as well as a blood displacement system 647 for controlling and/or tracking an infusion of transparent fluid into the hood 12.

Processor 631 may also be configured to handle several different processing functions to process various data. For instance, processor 631 may be configured to input commands registered with tissue surface images 633 as received from input device 651, as well as process catheter position data 635 based upon catheter tracking feedback signals as received from the movement tracking system 643 from guidance assembly 639. Moreover, processor 631 may be configured to process desired catheter articulations 637 in accordance with the commands received from the input device 651 such that drive signals are generated by processor 631 and transmitted to the articulation drive 641 in guidance assembly 639 to control the movements of the catheter and/or hood in a desired manner.

FIG. 48A illustrates a perspective view of a variation of a robotic control assembly showing base 602 having four proximal drive assemblies 630 attached thereupon where each assembly 630 may control a corresponding control element, e.g., pullwire, for controlling an articulation of hood 12 positioned upon deployment catheter 16. Delivery catheter or sheath 14 may be attached or otherwise coupled to base 602 or to sheath instrument 632 having an instrument base 636, which may also have a drive assembly 630 rotatably positioned thereon. The control elements attached to their respective drive assembly 630 may each extend through delivery catheter 14 and couple to the hood 12, as described below, to bend the distal end of the deployment catheter 16 and/or hood 12 itself in any number of directions by displacing one of the control elements in the proximal direction to deflect the distal end of the catheter member in the predetermined direction.

Catheter 14 may be coupled to instrument base 636 such that the drive assembly 630 may be used to control a retraction or advancement of the catheter 14 relative to hood 12 to control the expansion or collapse of hood 12. FIG. 48B shows a detail perspective view of the distal end of catheter 16 extending from delivery catheter 14 and articulation of the hood 12 relative to the catheter 16. In one variation, hood 12 may utilize imaging element 620, e.g., CMOS, CCD imager, etc., positioned off-axis relative to a longitudinal axis of catheter 16 and attached along one or more support struts 622 within hood 12. Hood 12 may be connected to hood base 640 which is pivotable in a first plane via hinge or pivot 642. Hood base 640 may itself be pivotable in a second plane via hinge or pivot 644 and the distal end of deployment catheter 16 may further define an articulatable section 638, which may allow its distal end to articulate within a plane when urged by the one or more control elements.

FIG. 48C illustrates a perspective view of another variation of a robotic control assembly having an inflatable imaging balloon 653 assembly. As shown, imaging balloon 653 may be positioned upon articulatable deployment catheter 16 and may further include a separate anchoring balloon 655 positioned upon support catheter 657 distally of imaging balloon 653. Support catheter 657 may extend through both anchoring balloon 655 and imaging balloon 653 and define a lumen 659 therethrough for accessing the tissue regions with any number of instruments 667. In use, support catheter 657 and anchoring balloon 655 (in its deflated state) may be advanced into a vessel lumen, e.g., through the ostium of a pulmonary vein, where anchoring balloon 655 may be inflated into contact against the surrounding vessel walls. With anchoring balloon 655 inflated, support catheter 657 may be independently translatable with respect to imaging balloon 653 (which may be inflated prior to, during, or after anchoring of the anchoring balloon 655) to allow for positional adjustment between imaging balloon 653 and the tissue surrounding the ostium.

Imaging balloon 653 may be inflated with a transparent fluid or gas, as described above, and may be further supported structurally by one or more support struts 665 extending distally from catheter 16 within or along a proximal portion of imaging balloon 653. During introduction and/or advancement through the patient body, support struts 665 may be collapsed along with imaging balloon 653 into a low-profile configuration and when deployed, balloon 653 may be inflated and support struts 665 may extend radially relative to catheter 16 to support imaging balloon 653. Additionally, support struts 665 may also support one or more light sources 661, e.g., light emitting diodes, optical fibers, etc. to provide illumination through imaging balloon 653 for viewing the underlying contacted tissue. Imaging element 663, as above, may also be supported along or upon a support strut 665 for viewing the tissue region through balloon 653 as well.

A partially disassembled view of the control element 606 spooled around a respective drive assembly 630 is illustrated in the perspective view of FIG. 49. As shown, each assembly 630 may comprise an axle 650 about which assembly 630 may rotate in a first direction to spool, and thus proximally displace an attached control element 606 to deflect the distal end of catheter 16 is a first direction, or rotate in a second opposite direction to unspool, and thus distally displace the attached control element 606 to deflect the distal end of catheter 16 in a second opposite direction.

The guide instrument 662 and sheath instrument 632 having deployment catheter 16 extending distally therefrom with hood 12 articulatably disposed upon the distal end of catheter 16 is illustrated in the perspective assembly view of FIG. 50. Both guide instrument 662 and instrument guide 632 are illustrated mounted upon instrument driver 660, which functions as a platform. Instrument driver 660 may also provide additional degrees of precision control movements for the visualization catheter system. FIG. 51 shows a partial disassembled perspective view of the instrument driver 660 assembly illustrating the main housing structure 670 underlying the assembly. As illustrated, cams and motors may be controlled by one or more electronics boards 672 which may be coupled to the main housing structure 670.

In yet another variation of a mechanism which provides precision steering and articulation of the hood 12 is shown in the perspective assembly view of FIG. 52A. A precision control drive unit 680 may be attached to delivery catheter 14 and/or deployment catheter 16 for providing articulation control. FIG. 52B illustrates a detailed perspective view of the distal end of one variation of deployment catheter 16 having the articulatable section 638. Hinge or pivot 642 and 644 may provide for articulation in at least two planes transverse to one another for viewing tissue structures via imaging element 620 positioned within hood 12, as described above. FIG. 53 illustrates an example of a simplified assembly view of the mechanisms within control drive unit 680 for controlling the articulation of hood 12. As shown, one or more pullwires 682 may be routed through catheter 14 to hood 12 with their proximal ends coupled to one or more cams 684 or gears. These cams 684 may be rotatably coupled to one or more drive wheels 686, which are in turn in communication through control cables 688 to (optional) gearing 692 of motor driver 690.

The examples illustrating precision control assemblies for articulating the hood 12 and/or catheter 16 are further described in detail in U.S. Pat. App. 2006/0084945 A1 and U.S. Pat. No. 7,090,613, each of which has been incorporated above in their entirety.

In enabling the precision control assemblies to steer hood 12 and/or catheter 16 in multiple degrees of freedom, various couplings between hood 12 and catheter 16 may be provided. One variation is illustrated in the detail perspective view of FIGS. 54A and 54B, which show an assembled view and exploded assembly view, respectively. In this variation, hood 12, having imaging element 620 positioned therewithin in an off-axis location, may be coupled or otherwise attached to hood base 640, which itself is pivotably coupled via hood mating portion 706 connected to receiving portion 708 via pin 710 to allow hood 12 to articulate within a first plane. Receiving portion 708 may also be pivotably coupled to receiving portion 702 via pin 704 to allow hood 12 to articulate within a second plane transverse to the first plane. The receiving portion 708 may also have one or more pullwire termination points 700 to which one or more pullwires 682 may be terminated.

FIGS. 55A and 55C shows another variation where a pair of pullwires 682 may steer a first planarly articulatable spine section 720 located near or at the distal end of deployment catheter 16. A second pair of pullwires 682 may steer hood base 640 and hood 12 in a second plane transverse to the first plane. The steerable spine section 720 may comprise a spine segment 722 having multiple cut-outs or reduced sections 724 along either side of the spine segment 722 such that the spine section 720 may bend in a plane by flexing to either side of the reduced sections 724 while maintaining structural integrity by the spine segment 722, as illustrated in the detail view of FIG. 55B. Spine section 720 may be comprised of various materials, e.g., stainless steel, PEEK or hard plastics, through machining, molding or metal injection molding. Moreover, stainless steel cables, Nitinol, elgiloy, or tungsten wires can be used for pullwires. The section 720 can be alternatively constructed as bump links, pinned links, ring links, laser cut tubes, fish bone spine links, slit tubes or double durometer tubes, etc., may also be steered using various mechanisms such as single bend steering, double bend steering with two or more pullwires, multi-way bend steering, and/or steering through multiple variations of catheter-sheath interactions.

FIGS. 56A and 56C illustrate yet another variation of steering mechanisms in the perspective assembly and exploded assembly views. In this variation, a fully articulatable spine section 730 may be included near or at the distal end of deployment catheter 16, as above, where the section 730 includes a central spine 734 having multiple cut-outs or reduced sections 732 circumferentially defined about central spine 734, as illustrated in FIG. 56B. Having the reduced sections 732 defined entirely around spine 734 enables full articulation of hood 12 about spine 734 rather than being limited for movement within a plane.

While utilizing a computer-controller for articulating the assembly, the computer may also track the movement of hood 12 within a patient body, e.g., within the left atrial chamber of the heart, such that the location and position relative to an anatomical landmark, e.g., the pulmonary veins, are known at any given time. Other alternative mechanisms may also be utilized to track and/or record the position of hood 12 within the body at any given time.

For instance, FIG. 57A shows a perspective view of one such variation where a ferromagnetic ring 740 may be attached circumferentially around the lip of hood 12. Such a configuration may be utilized in conjunction with conventional magnetic navigation systems, such as the NIOBE® system developed by Stereotaxis, Inc. (Saint Louis, Mo.), as illustrated in the perspective view of FIG. 57B. An example of such a magnetic navigation system is shown and described in U.S. Pat. No. 7,019,610 (Creighton et al.) which is incorporated herein by reference in its entirety. Generally, an arrangement of two magnets 746, 748 may be positioned externally to the patient. With external control by an operator, the two magnets 746, 748 may swing into position on each side of the patient creating a magnetic field that directs and digitally controls either the distal tip of the tissue visualization catheter or, in this case, the ferromagnetic ring 740 positioned about the lip of hood 12. By rotating and moving the external magnets 746, 748 to change the direction of the magnetic field, the system automatically controls the catheter advancement and retraction of the visualization catheter, eliminating any pulling or pushing on the device. This may be particularly advantageous when the tissue visualization catheter is threaded through tortuous pathways where force transmission is greatly reduced, consequently affecting accuracy in navigational control that requires the pushing or pulling of the sheath or navigation that requires steering internal pullwires.

FIG. 58 shows a perspective view of yet another variation of the tissue visualization catheter which is configured to detect the position and/or orientation of the hood 12 through the use of existing ultrasound technologies as described in. e.g., U.S. Pat. No. 5,515,853, which is incorporated herein by reference in its entirety. As shown, a first 750 and second 752 ultrasound signal transducer may be symmetrically attached to the hood 12 around the circumference of the lip of hood 12, while a third ultrasound transducer 754 may be placed between the tip of the deployment catheter 16 and the proximal end of the hood 12.

A ferromagnetic ring or an electromagnetic coil 740 that is able to interact with a magnetic field to pull the hood towards a tissue surface may also be attached to the circumference of the hood 12. Alternatively, the struts 758 supporting hood 12 may be made of a ferromagnetic material where one or more of the struts 758 may have electromagnetic coils 756 wound around the struts 758, as shown in the perspective view of FIG. 59. In yet another alternative, a ferromagnetic disc 760 positioned upon a support member 762 extending through hood 12 may also be utilized, as shown in the perspective view of FIG. 60. In these or other variations of hood 12, a circumferential balloon 742 which is inflatably positioned within hood 12 and which defines a lumen or channel 744 through the inflated balloon 742 may be optionally utilized. Such a balloon 742 is described in further detail in U.S. patent application Ser. No. 11/775,771 filed Jul. 10, 2007, which is incorporated herein by reference in its entirety.

In either case, the ferromagnetic or electromagnetic feature and the ultrasound signal transducers 750, 752, 754 along hood 12 may be used with a position sensor assembly 770, as shown in the perspective view of FIG. 61. Position sensor assembly 770 may generally comprise a plate 772 made of radio-transparent material which may be positioned externally of a patient along a skin surface proximate or adjacent to where the hood 12 is to be controlled or tracked within the patient body. Plate 772 may have three or more ultrasound transducers 778, 780, 782 positioned along the plate surface separated by a known distance from one another. An electromagnet 776 attached to handle 774 may be slidably positioned within plate 772 for controlling a position of hood 12 within the patient body, as described below.

Generally, each of the ultrasound transducers 750, 752, 754 positioned along hood 12 may communicate with the ultrasound transducers 778, 780, 782 on the plate 772 to determine their relative distances from one other by measuring the time between transmission and detection of the ultrasound signals, as illustrated in FIG. 62. By triangulation methods, the position of each transducer along hood 12 relative to each transducer along plate 772, the three-dimensional orientation and position of the hood 12 within the patient body may be computationally determined by a processor and displayed graphically or otherwise to the user. The user may determine an orientation of the hood 12, for instance if the hood 12 is facing the external plate 772 within the patient body, when 750 and 752 are of equal distance to the plate 772. Similarly using the same triangulation method, the position of the hood 12 can be determined. Moreover, knowing which quadrant 790, 792, 794, 796 of the plate the hood 12 is relatively positioned may be utilized in differentiating between particular anatomical features, e.g., determining which of the four pulmonary veins the user may be viewing in a patient's heart utilizing the imaging element within hood 12, as described above.

Detailed examples are further shown and described in U.S. Pat. No. 5,515,853, which is incorporated herein above. Additionally, although three transducers are illustrated in the example on hood 12 as well as plate 772, additional transducers may be optionally utilized.

Moreover, in activating the electromagnet 776, e.g., by a foot pedal, the ferromagnetic element located on the hood 12 may be drawn via magnetic attraction towards the externally located plate 772 such that hood 12 is consequently drawn against the internal tissue surface. By drawing the hood 12 against the internal tissue surface, hood 12 may be positioned or articulated against the tissue surface by the externally located handle 774 and electromagnet 776 to facilitate movement of the hood 12 along tissue walls.

An example is illustrated in FIGS. 63A to 63C which shows hood 12 having circumferential ferromagnetic ring 740 positioned thereon located within the left atrium LA of heart H. In placing plate 772 of assembly 770 against the external skin surface S of the patient body (e.g., behind the back of the patient, in a position directly below the heart H, or any other position on the patient body where a visualization catheter is to be advanced along, into, or through an underlying organ or body lumen), a layer of ultrasound coupling gel may be applied between the skin S and the external plate 772, to ensure that ultrasound signals are conducted efficiently. After entry of hood 12 within left atrium LA, the orientation and position of the hood 12 may be determined via triangulation relative to plate assembly 770, as shown in FIG. 63A. Upon orienting the hood 12 in a desired orientation and/or position, the movable electromagnet 776 in the external plate 772 can be magnetized, e.g., by stepping on a foot pedal, to draw the electromagnetic ring 740 and hood 12 towards the tissue wall, as shown in FIG. 63B. With the hood 12 positioned upon the tissue wall, handle 774 and electromagnet 776 may be moved in a direction 800 within plate 772 to “walk” or move hood 12 along the tissue wall in a corresponding direction 800′. While hood 12 is drawn against the tissue wall, the open area may be purged of blood and the underlying tissue may be viewed through imaging element 620, as described above.

Another variation is illustrated in the partial cross-sectional view of FIG. 64, which illustrates an example where rather than utilizing ultrasound transducers along an externally located plate, a catheter 810 having at least three transducers 812, 814, 816 at known distances from one another may be intravascularly advanced, e.g., into the coronary sinus CS of a patient heart and positioned such that the transducers are located about the mitral valve. Temporarily positioning the transducers 812, 814, 816 within the coronary sinus CS, where they are in closer proximity with the transducers on the hood 12, may reduce the loss of ultrasound signals to the environment as compared to having transducers placed outside the body. Moreover, having the transducers communicating within the body also removes the need for ultrasound coupling gel to be applied on the patient's skin.

The applications of the disclosed invention discussed above are not limited to certain treatments or regions of the body, but may include any number of other treatments and areas of the body. Modification of the above-described methods and devices for carrying out the invention, and variations of aspects of the invention that are obvious to those of skill in the arts are intended to be within the scope of this disclosure. Moreover, various combinations of aspects between examples are also contemplated and are considered to be within the scope of this disclosure as well.

Claims

1. A robotic assembly comprising: a delivery catheter defining at least one lumen therethrough;a deployment catheter that is positionable through the at least one lumen of the delivery catheter, the deployment catheter defining a longitudinal axis and including a steerable distal region;a balloon assembly including a first balloon and a second balloon, the second balloon including a proximal end coupled at a distal tip of the steerable distal region of the deployment catheter, wherein the second balloon is inflatable to extend beyond the longitudinal axis of the deployment catheter and distally of the distal tip of the steerable distal region of the deployment catheter; anda support catheter extending through the first and second balloons and defining a lumen therethrough, wherein the first balloon is fixed to the support catheter and wherein a position of the second balloon, inflated distally of the distal tip of the steerable distal region of the deployment catheter, is adjustable along the support catheter proximal of the first balloon.
2. The robotic assembly of claim 1 wherein the second balloon of the balloon assembly includes an imaging balloon.
3. The robotic assembly of claim 2 wherein the first balloon of the balloon assembly includes an anchoring balloon coupled to the support catheter distally from the imaging balloon.
4. The robotic assembly of claim 3 wherein the anchoring balloon is inflatable independently of the imaging balloon.
5. The robotic assembly of claim 3 wherein the support catheter extends between the imaging balloon and the anchoring balloon.
6. The robotic assembly of claim 5 wherein the lumen of the support catheter is configured for passage through the imaging and anchoring balloons to a region distal of the anchoring balloon.
7. The robotic assembly of claim 1 wherein the balloon assembly is inflatable into contact with surrounding tissue.
8. The robotic assembly of claim 1 wherein the balloon assembly supports an energy source.
9. The robotic assembly of claim 8 wherein the energy source comprises a light emitting diode or an optical fiber.
10. The robotic assembly of claim 1 further comprising a control element for articulating the steerable distal region.
11. The robotic assembly of claim 10 wherein the control element includes a pull wire.
12. The robotic assembly of claim 11 wherein the pull wire is spooled around a drive assembly.
13. The robotic assembly of claim 1 further comprising an imaging element coupled to the balloon assembly.
14. The robotic assembly of claim 1, wherein the second balloon further includes a distal end spaced distally apart from the distal tip of the steerable distal region of the deployment catheter.
15. The robotic assembly of claim 14, wherein the distal end of the second balloon includes an aperture through which the support catheter extends.
16. The robotic assembly of claim 1, wherein balloon assembly further includes a support strut configured to support the second balloon, the support strut extending distally from the deployment catheter.
17. The robotic assembly of claim 16, wherein the support strut extends along a proximal portion of the second balloon.
18. The robotic assembly of claim 16, wherein the balloon assembly includes a plurality of radially extending support struts configured to support the second balloon, the plurality of radially extending support struts including the support strut, wherein the plurality of radially extending support struts extend distally from the deployment catheter.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation of U.S. patent application Ser. No. 12/464,800 filed May 12, 2009 which is a continuation of U.S. patent application Ser. No. 11/848,429 filed Aug. 31, 2007 which claims the benefit of priority to U.S. Prov. Pat. App. 60/824,421 filed Sep. 1, 2006 and to U.S. Prov. Pat. App. 60/916,640 filed May 8, 2007, each of which is incorporated herein by reference in its entirety.

US Referenced Citations (678)

Number	Name	Date	Kind
623002	Fitzgerald	Apr 1899	A
623022	Johnson	Apr 1899	A
2305462	Wolf	Dec 1942	A
2453862	Salisbury	Nov 1948	A
3559651	Moss	Feb 1971	A
3831587	Boyd	Aug 1974	A
3874388	King et al.	Apr 1975	A
3903877	Terada	Sep 1975	A
4175545	Termanini	Nov 1979	A
4198981	Sinnreich	Apr 1980	A
4326529	Doss et al.	Apr 1982	A
4403612	Fogarty	Sep 1983	A
4445892	Hussein et al.	May 1984	A
4470407	Hussein	Sep 1984	A
4517976	Murakoshi et al.	May 1985	A
4569335	Tsuno	Feb 1986	A
4576146	Kawazoe et al.	Mar 1986	A
4615333	Taguchi	Oct 1986	A
4619247	Inoue et al.	Oct 1986	A
4676258	Inokuchi et al.	Jun 1987	A
4681093	Ono et al.	Jul 1987	A
4696668	Wilcox	Sep 1987	A
4709698	Johnston et al.	Dec 1987	A
4710192	Liotta et al.	Dec 1987	A
4727418	Kato et al.	Feb 1988	A
4772260	Heyden	Sep 1988	A
4784133	Mackin	Nov 1988	A
4838246	Hahn et al.	Jun 1989	A
4848323	Marijnissen et al.	Jul 1989	A
4880015	Nierman	Nov 1989	A
4911148	Sosnowski et al.	Mar 1990	A
4914521	Adair	Apr 1990	A
4943290	Rexroth et al.	Jul 1990	A
4950285	Wilk	Aug 1990	A
4957484	Murtfeldt	Sep 1990	A
4960411	Buchbinder	Oct 1990	A
4961738	Mackin	Oct 1990	A
4976710	Mackin	Dec 1990	A
4991578	Cohen	Feb 1991	A
4994069	Ritchart et al.	Feb 1991	A
4998916	Hammerslag et al.	Mar 1991	A
4998972	Chin et al.	Mar 1991	A
5025778	Silverstein et al.	Jun 1991	A
5047028	Qian	Sep 1991	A
5057106	Kasevich et al.	Oct 1991	A
5090959	Samson et al.	Feb 1992	A
5123428	Schwarz	Jun 1992	A
RE34002	Adair	Jul 1992	E
5156141	Krebs et al.	Oct 1992	A
5171259	Inoue	Dec 1992	A
5197457	Adair	Mar 1993	A
5270810	Nishimura	Dec 1993	A
5281238	Chin et al.	Jan 1994	A
5282827	Kensey et al.	Feb 1994	A
5305121	Moll	Apr 1994	A
5306234	Johnson	Apr 1994	A
5313934	Wiita et al.	May 1994	A
5313943	Houser et al.	May 1994	A
5330496	Alferness	Jul 1994	A
5334159	Turkel	Aug 1994	A
5334193	Nardella	Aug 1994	A
5336252	Cohen	Aug 1994	A
5339800	Wiita et al.	Aug 1994	A
5345927	Bonutti	Sep 1994	A
5348554	Imran et al.	Sep 1994	A
5353792	Luebbers et al.	Oct 1994	A
5370647	Graber et al.	Dec 1994	A
5373840	Knighton	Dec 1994	A
5375612	Cottenceau et al.	Dec 1994	A
5385146	Goldreyer	Jan 1995	A
5385148	Lesh et al.	Jan 1995	A
5391182	Chin	Feb 1995	A
5391199	Ben-Haim	Feb 1995	A
5403311	Abele et al.	Apr 1995	A
5403326	Harrison et al.	Apr 1995	A
5405360	Tovey	Apr 1995	A
5405376	Mulier et al.	Apr 1995	A
5409483	Campbell et al.	Apr 1995	A
5411016	Kume et al.	May 1995	A
5413104	Buijs et al.	May 1995	A
5421338	Crowley et al.	Jun 1995	A
5431649	Mulier et al.	Jul 1995	A
5453785	Lenhardt et al.	Sep 1995	A
5458612	Chin	Oct 1995	A
5462521	Brucker et al.	Oct 1995	A
5471515	Fossum et al.	Nov 1995	A
5484412	Pierpont	Jan 1996	A
5498230	Adair	Mar 1996	A
5505730	Edwards	Apr 1996	A
5515853	Smith et al.	May 1996	A
5527338	Purdy	Jun 1996	A
5549603	Feiring	Aug 1996	A
5558619	Kami et al.	Sep 1996	A
5571088	Lennox et al.	Nov 1996	A
5575756	Karasawa et al.	Nov 1996	A
5575810	Swanson et al.	Nov 1996	A
5584872	Lafontaine et al.	Dec 1996	A
5591119	Adair	Jan 1997	A
5593405	Osypka	Jan 1997	A
5593422	Muijs et al.	Jan 1997	A
5593424	Northrup III	Jan 1997	A
5643282	Kieturakis	Jul 1997	A
5653677	Okada et al.	Aug 1997	A
5662671	Barbut et al.	Sep 1997	A
5665062	Houser	Sep 1997	A
5672153	Lax et al.	Sep 1997	A
5676693	Lafontaine	Oct 1997	A
5681308	Edwards et al.	Oct 1997	A
5695448	Kimura et al.	Dec 1997	A
5697281	Eggers et al.	Dec 1997	A
5697882	Eggers et al.	Dec 1997	A
5709224	Behl et al.	Jan 1998	A
5713907	Hogendijk et al.	Feb 1998	A
5713946	Ben-Haim	Feb 1998	A
5716321	Kerin et al.	Feb 1998	A
5716325	Bonutti	Feb 1998	A
5722403	McGee et al.	Mar 1998	A
5725523	Mueller	Mar 1998	A
5743851	Moll et al.	Apr 1998	A
5746747	McKeating	May 1998	A
5749846	Edwards et al.	May 1998	A
5749889	Bacich et al.	May 1998	A
5749890	Shaknovich	May 1998	A
5754313	Pelchy et al.	May 1998	A
5766137	Omata	Jun 1998	A
5769846	Edwards et al.	Jun 1998	A
5792045	Adair	Aug 1998	A
5797903	Swanson et al.	Aug 1998	A
5823947	Yoon et al.	Oct 1998	A
5827175	Tanaka et al.	Oct 1998	A
5827268	Laufer	Oct 1998	A
5829447	Stevens et al.	Nov 1998	A
5842973	Bullard	Dec 1998	A
5843118	Sepetka et al.	Dec 1998	A
5846221	Snoke et al.	Dec 1998	A
5846239	Swanson et al.	Dec 1998	A
5848969	Panescu et al.	Dec 1998	A
5860974	Abele	Jan 1999	A
5860991	Klein et al.	Jan 1999	A
5865791	Whayne et al.	Feb 1999	A
5873815	Kerin et al.	Feb 1999	A
5879366	Shaw et al.	Mar 1999	A
5895417	Pomeranz et al.	Apr 1999	A
5897487	Ouchi	Apr 1999	A
5897553	Mulier et al.	Apr 1999	A
5902328	Lafontaine et al.	May 1999	A
5904651	Swanson et al.	May 1999	A
5908445	Whayne et al.	Jun 1999	A
5916147	Boury	Jun 1999	A
5925038	Panescu et al.	Jul 1999	A
5928250	Koike et al.	Jul 1999	A
5929901	Adair et al.	Jul 1999	A
5937614	Watkins et al.	Aug 1999	A
5941845	Tu et al.	Aug 1999	A
5944690	Falwell et al.	Aug 1999	A
5964755	Edwards	Oct 1999	A
5968053	Revelas	Oct 1999	A
5971983	Lesh	Oct 1999	A
5980484	Ressemann et al.	Nov 1999	A
5985307	Hanson et al.	Nov 1999	A
5986693	Adair et al.	Nov 1999	A
5997571	Farr et al.	Dec 1999	A
6004269	Crowley et al.	Dec 1999	A
6007521	Bidwell et al.	Dec 1999	A
6012457	Lesh	Jan 2000	A
6013024	Mitsuda et al.	Jan 2000	A
6024740	Lesh et al.	Feb 2000	A
6027501	Goble et al.	Feb 2000	A
6036685	Mueller	Mar 2000	A
6043839	Adair et al.	Mar 2000	A
6047218	Whayne et al.	Apr 2000	A
6063077	Schaer	May 2000	A
6063081	Mulier et al.	May 2000	A
6068653	Lafontaine	May 2000	A
6071279	Whayne et al.	Jun 2000	A
6071302	Sinofsky et al.	Jun 2000	A
6081740	Gombrich et al.	Jun 2000	A
6086528	Adair	Jul 2000	A
6086534	Kesten	Jul 2000	A
6099498	Addis	Aug 2000	A
6099514	Sharkey et al.	Aug 2000	A
6102905	Baxter et al.	Aug 2000	A
6112123	Kelleher et al.	Aug 2000	A
6115626	Whayne et al.	Sep 2000	A
6123703	Tu et al.	Sep 2000	A
6123718	Tu et al.	Sep 2000	A
6129724	Fleischman et al.	Oct 2000	A
6139508	Simpson et al.	Oct 2000	A
6142993	Whayne et al.	Nov 2000	A
6152144	Lesh et al.	Nov 2000	A
6156350	Constantz	Dec 2000	A
6159203	Sinofsky	Dec 2000	A
6161543	Cox et al.	Dec 2000	A
6164283	Lesh	Dec 2000	A
6167297	Benaron	Dec 2000	A
6168591	Sinofsky	Jan 2001	B1
6168594	Lafontaine et al.	Jan 2001	B1
6174307	Daniel et al.	Jan 2001	B1
6178346	Amundson et al.	Jan 2001	B1
6190381	Olsen et al.	Feb 2001	B1
6211904	Adair et al.	Apr 2001	B1
6224553	Nevo	May 2001	B1
6231561	Frazier et al.	May 2001	B1
6234995	Peacock, III	May 2001	B1
6235044	Root et al.	May 2001	B1
6237605	Vaska et al.	May 2001	B1
6238393	Mulier et al.	May 2001	B1
6240312	Alfano et al.	May 2001	B1
6254598	Edwards et al.	Jul 2001	B1
6258083	Daniel et al.	Jul 2001	B1
6261226	McKenna et al.	Jul 2001	B1
6263224	West	Jul 2001	B1
6266551	Osadchy et al.	Jul 2001	B1
6270492	Sinofsky	Aug 2001	B1
6275255	Adair et al.	Aug 2001	B1
6280450	McGuckin, Jr.	Aug 2001	B1
6290689	Delaney et al.	Sep 2001	B1
6306081	Ishikawa et al.	Oct 2001	B1
6310642	Adair et al.	Oct 2001	B1
6311692	Vaska et al.	Nov 2001	B1
6314962	Vaska et al.	Nov 2001	B1
6314963	Vaska et al.	Nov 2001	B1
6315777	Comben	Nov 2001	B1
6315778	Gambale et al.	Nov 2001	B1
6322536	Rosengart et al.	Nov 2001	B1
6325797	Stewart et al.	Dec 2001	B1
6328727	Frazier et al.	Dec 2001	B1
6352503	Matsui et al.	Mar 2002	B1
6358247	Altman et al.	Mar 2002	B1
6358248	Mulier et al.	Mar 2002	B1
6375654	McIntyre	Apr 2002	B1
6379345	Constantz	Apr 2002	B1
6383195	Richard	May 2002	B1
6385476	Osadchy et al.	May 2002	B1
6387043	Yoon	May 2002	B1
6387071	Constantz	May 2002	B1
6394096	Constantz	May 2002	B1
6396873	Goldstein et al.	May 2002	B1
6398780	Farley et al.	Jun 2002	B1
6401719	Farley et al.	Jun 2002	B1
6409722	Hoey et al.	Jun 2002	B1
6416511	Lesh et al.	Jul 2002	B1
6419669	Frazier et al.	Jul 2002	B1
6423051	Kaplan et al.	Jul 2002	B1
6423055	Farr et al.	Jul 2002	B1
6423058	Edwards et al.	Jul 2002	B1
6428536	Panescu et al.	Aug 2002	B2
6436118	Kayan	Aug 2002	B1
6440061	Wenner et al.	Aug 2002	B1
6440119	Nakada et al.	Aug 2002	B1
6458151	Saltiel	Oct 2002	B1
6461327	Addis et al.	Oct 2002	B1
6464697	Edwards et al.	Oct 2002	B1
6474340	Vaska et al.	Nov 2002	B1
6475223	Werp et al.	Nov 2002	B1
6478769	Parker	Nov 2002	B1
6482162	Moore	Nov 2002	B1
6484727	Vaska et al.	Nov 2002	B1
6485489	Teirstein et al.	Nov 2002	B2
6488671	Constantz et al.	Dec 2002	B1
6494902	Hoey et al.	Dec 2002	B2
6497651	Kan et al.	Dec 2002	B1
6497705	Comben	Dec 2002	B2
6500174	Maguire et al.	Dec 2002	B1
6502576	Lesh	Jan 2003	B1
6514249	Maguire et al.	Feb 2003	B1
6517533	Swaminathan	Feb 2003	B1
6527979	Constantz et al.	Mar 2003	B2
6532380	Close et al.	Mar 2003	B1
6533767	Johansson et al.	Mar 2003	B2
6537272	Christopherson et al.	Mar 2003	B2
6538375	Duggal et al.	Mar 2003	B1
6540733	Constantz et al.	Apr 2003	B2
6540744	Hassett et al.	Apr 2003	B2
6544195	Wilson et al.	Apr 2003	B2
6547780	Sinofsky	Apr 2003	B1
6549800	Atalar et al.	Apr 2003	B1
6558375	Sinofsky et al.	May 2003	B1
6558382	Jahns et al.	May 2003	B2
6562020	Constantz et al.	May 2003	B1
6572609	Farr et al.	Jun 2003	B1
6579285	Sinofsky	Jun 2003	B2
6585732	Mulier et al.	Jul 2003	B2
6587709	Solf et al.	Jul 2003	B2
6593884	Gilboa et al.	Jul 2003	B1
6605055	Sinofsky et al.	Aug 2003	B1
6613062	Leckrone et al.	Sep 2003	B1
6622732	Constantz	Sep 2003	B2
6626855	Weng et al.	Sep 2003	B1
6626899	Houser et al.	Sep 2003	B2
6626900	Sinofsky et al.	Sep 2003	B1
6632171	Iddan et al.	Oct 2003	B2
6635070	Leeflang et al.	Oct 2003	B2
6645202	Pless et al.	Nov 2003	B1
6650923	Lesh et al.	Nov 2003	B1
6658279	Swanson et al.	Dec 2003	B2
6659940	Adler	Dec 2003	B2
6663821	Seward	Dec 2003	B2
6673090	Root et al.	Jan 2004	B2
6676656	Sinofsky	Jan 2004	B2
6679836	Couvillon, Jr. et al.	Jan 2004	B2
6682526	Jones et al.	Jan 2004	B1
6689051	Nakada et al.	Feb 2004	B2
6689128	Sliwa et al.	Feb 2004	B2
6692430	Adler	Feb 2004	B2
6701581	Senovich et al.	Mar 2004	B2
6701931	Sliwa et al.	Mar 2004	B2
6702780	Gilboa et al.	Mar 2004	B1
6704043	Goldstein et al.	Mar 2004	B2
6706039	Mulier et al.	Mar 2004	B2
6712798	Constantz	Mar 2004	B2
6719747	Constantz et al.	Apr 2004	B2
6719755	Sliwa et al.	Apr 2004	B2
6730063	Delaney et al.	May 2004	B2
6736810	Hoey et al.	May 2004	B2
6749617	Palasis et al.	Jun 2004	B1
6751492	Ben-Haim	Jun 2004	B2
6755790	Stewart et al.	Jun 2004	B2
6755811	Constantz	Jun 2004	B1
6764487	Mulier et al.	Jul 2004	B2
6770070	Balbierz	Aug 2004	B1
6771996	Bowe et al.	Aug 2004	B2
6773402	Govari et al.	Aug 2004	B2
6780151	Grabover et al.	Aug 2004	B2
6805128	Pless et al.	Oct 2004	B1
6805129	Pless et al.	Oct 2004	B1
6811562	Pless	Nov 2004	B1
6833814	Gilboa et al.	Dec 2004	B2
6840923	Lapcevic	Jan 2005	B1
6840936	Sliwa et al.	Jan 2005	B2
6849073	Hoey et al.	Feb 2005	B2
6858005	Ohline et al.	Feb 2005	B2
6858026	Sliwa et al.	Feb 2005	B2
6858905	Hsu et al.	Feb 2005	B2
6863668	Gillespie et al.	Mar 2005	B2
6866651	Constantz	Mar 2005	B2
6887237	McGaffigan	May 2005	B2
6892091	Ben-Haim et al.	May 2005	B1
6896690	Lambrecht et al.	May 2005	B1
6899672	Chin et al.	May 2005	B2
6915154	Docherty et al.	Jul 2005	B1
6916284	Moriyama	Jul 2005	B2
6916286	Kazakevich	Jul 2005	B2
6923805	Lafontaine et al.	Aug 2005	B1
6929010	Vaska et al.	Aug 2005	B2
6932809	Sinofsky	Aug 2005	B2
6939348	Malecki et al.	Sep 2005	B2
6942657	Sinofsky et al.	Sep 2005	B2
6949095	Vaska et al.	Sep 2005	B2
6953457	Farr et al.	Oct 2005	B2
6955173	Lesh	Oct 2005	B2
6958069	Shipp et al.	Oct 2005	B2
6962589	Mulier et al.	Nov 2005	B2
6971394	Sliwa et al.	Dec 2005	B2
6974464	Quijano et al.	Dec 2005	B2
6979290	Mourlas et al.	Dec 2005	B2
6982740	Adair et al.	Jan 2006	B2
6984232	Vanney et al.	Jan 2006	B2
6994094	Schwartz	Feb 2006	B2
7001329	Kobayashi et al.	Feb 2006	B2
7019610	Creighton et al.	Mar 2006	B2
7025746	Tal	Apr 2006	B2
7030904	Adair et al.	Apr 2006	B2
7041098	Farley et al.	May 2006	B2
7042487	Nakashima	May 2006	B2
7044135	Lesh	May 2006	B2
7052493	Vaska et al.	May 2006	B2
7090683	Brock et al.	Aug 2006	B2
7118566	Jahns	Oct 2006	B2
7156845	Mulier et al.	Jan 2007	B2
7163534	Brucker et al.	Jan 2007	B2
7166537	Jacobsen et al.	Jan 2007	B2
7169144	Hoey et al.	Jan 2007	B2
7179224	Willis	Feb 2007	B2
7186214	Ness	Mar 2007	B2
7207984	Farr et al.	Apr 2007	B2
7217268	Eggers et al.	May 2007	B2
7242832	Carlin et al.	Jul 2007	B2
7247155	Hoey et al.	Jul 2007	B2
7261711	Mulier et al.	Aug 2007	B2
7263397	Hauck et al.	Aug 2007	B2
7276061	Schaer et al.	Oct 2007	B2
7309328	Kaplan et al.	Dec 2007	B2
7322934	Miyake et al.	Jan 2008	B2
7323001	Clubb et al.	Jan 2008	B2
7416552	Paul et al.	Aug 2008	B2
7435248	Taimisto et al.	Oct 2008	B2
7527625	Knight et al.	May 2009	B2
7534204	Starksen et al.	May 2009	B2
7534294	Gaynor et al.	May 2009	B1
7569052	Phan et al.	Aug 2009	B2
7569952	Bono et al.	Aug 2009	B1
7736347	Kaplan et al.	Jun 2010	B2
7758499	Adler	Jul 2010	B2
7860555	Saadat	Dec 2010	B2
7860556	Saadat	Dec 2010	B2
7918787	Saadat	Apr 2011	B2
7919610	Serebriiskii et al.	Apr 2011	B2
7930016	Saadat	Apr 2011	B1
8050746	Saadat et al.	Nov 2011	B2
8078266	Saadat et al.	Dec 2011	B2
8131350	Saadat et al.	Mar 2012	B2
8137333	Saadat et al.	Mar 2012	B2
8221310	Saadat et al.	Jul 2012	B2
8235985	Saadat et al.	Aug 2012	B2
8333012	Rothe et al.	Dec 2012	B2
8417321	Saadat et al.	Apr 2013	B2
8419613	Saadat et al.	Apr 2013	B2
8475361	Barlow et al.	Jul 2013	B2
8657805	Peh et al.	Feb 2014	B2
8758229	Saadat et al.	Jun 2014	B2
8814845	Saadat et al.	Aug 2014	B2
8906007	Bonn et al.	Dec 2014	B2
8934962	Saadat et al.	Jan 2015	B2
9055906	Saadat et al.	Jun 2015	B2
9155587	Willis et al.	Oct 2015	B2
9192287	Saadat et al.	Nov 2015	B2
9226648	Saadat et al.	Jan 2016	B2
9332893	Saadat et al.	May 2016	B2
9510732	Miller et al.	Dec 2016	B2
9526401	Saadat et al.	Dec 2016	B2
10004388	Saadat et al.	Jun 2018	B2
10064540	Saadat et al.	Sep 2018	B2
10070772	Peh et al.	Sep 2018	B2
10092172	Peh et al.	Oct 2018	B2
10278588	Saadat et al.	May 2019	B2
10368729	Miller et al.	Aug 2019	B2
10390685	Saadat et al.	Aug 2019	B2
10463237	Saadat et al.	Nov 2019	B2
10470643	Saadat et al.	Nov 2019	B2
10555788	Panescu et al.	Feb 2020	B2
10772492	Miller et al.	Sep 2020	B2
11304771	Panescu et al.	Apr 2022	B2
11337594	Saadat et al.	May 2022	B2
11406250	Saadat et al.	Aug 2022	B2
11478152	Saadat et al.	Oct 2022	B2
20010020126	Swanson et al.	Sep 2001	A1
20010039416	Moorman et al.	Nov 2001	A1
20010047136	Domanik et al.	Nov 2001	A1
20010047184	Connors	Nov 2001	A1
20020004644	Koblish	Jan 2002	A1
20020026145	Bagaoisan et al.	Feb 2002	A1
20020035311	Ouchi	Mar 2002	A1
20020054852	Cate	May 2002	A1
20020065455	Ben-Haim et al.	May 2002	A1
20020072710	Stewart et al.	Jun 2002	A1
20020077594	Chien et al.	Jun 2002	A1
20020077642	Patel et al.	Jun 2002	A1
20020087169	Brock et al.	Jul 2002	A1
20020091304	Ogura et al.	Jul 2002	A1
20020138088	Nash et al.	Sep 2002	A1
20020161377	Rabkin et al.	Oct 2002	A1
20020165598	Wahr et al.	Nov 2002	A1
20020169377	Khairkhahan et al.	Nov 2002	A1
20020173815	Hogendijk	Nov 2002	A1
20030009085	Arai et al.	Jan 2003	A1
20030014010	Carpenter et al.	Jan 2003	A1
20030018358	Saadat	Jan 2003	A1
20030035156	Cooper	Feb 2003	A1
20030036698	Kohler et al.	Feb 2003	A1
20030065267	Smith	Apr 2003	A1
20030069593	Tremulis et al.	Apr 2003	A1
20030120142	Dubuc et al.	Jun 2003	A1
20030130572	Phan et al.	Jul 2003	A1
20030144657	Bowe et al.	Jul 2003	A1
20030171741	Ziebol et al.	Sep 2003	A1
20030181939	Bonutti	Sep 2003	A1
20030208222	Zadno-Azizi	Nov 2003	A1
20030212394	Pearson et al.	Nov 2003	A1
20030220574	Markus et al.	Nov 2003	A1
20030222325	Jacobsen et al.	Dec 2003	A1
20030236493	Mauch	Dec 2003	A1
20040044350	Martin et al.	Mar 2004	A1
20040049211	Tremulis et al.	Mar 2004	A1
20040054335	Lesh et al.	Mar 2004	A1
20040054389	Osypka	Mar 2004	A1
20040082833	Adler et al.	Apr 2004	A1
20040097792	Moll et al.	May 2004	A1
20040097805	Verard et al.	May 2004	A1
20040098031	van der Burg et al.	May 2004	A1
20040117032	Roth	Jun 2004	A1
20040133113	Krishnan	Jul 2004	A1
20040138529	Wiltshire et al.	Jul 2004	A1
20040138707	Greenhalgh	Jul 2004	A1
20040147806	Adler	Jul 2004	A1
20040147911	Sinofsky	Jul 2004	A1
20040147912	Sinofsky	Jul 2004	A1
20040147913	Sinofsky	Jul 2004	A1
20040158143	Flaherty et al.	Aug 2004	A1
20040158289	Girouard et al.	Aug 2004	A1
20040165766	Goto	Aug 2004	A1
20040167503	Sinofsky	Aug 2004	A1
20040181237	Forde et al.	Sep 2004	A1
20040199052	Banik et al.	Oct 2004	A1
20040210111	Okada	Oct 2004	A1
20040210239	Nash et al.	Oct 2004	A1
20040210278	Boll et al.	Oct 2004	A1
20040215180	Starkebaum et al.	Oct 2004	A1
20040220471	Schwartz	Nov 2004	A1
20040230131	Kassab et al.	Nov 2004	A1
20040248837	Raz et al.	Dec 2004	A1
20040249367	Saadat et al.	Dec 2004	A1
20040254523	Fitzgerald et al.	Dec 2004	A1
20040260182	Zuluaga et al.	Dec 2004	A1
20040267084	Navia et al.	Dec 2004	A1
20050004597	McGuckin et al.	Jan 2005	A1
20050014995	Amundson et al.	Jan 2005	A1
20050015048	Chiu et al.	Jan 2005	A1
20050020914	Amundson et al.	Jan 2005	A1
20050027163	Chin et al.	Feb 2005	A1
20050038419	Arnold et al.	Feb 2005	A9
20050059862	Phan	Mar 2005	A1
20050059954	Constantz	Mar 2005	A1
20050059965	Eberl et al.	Mar 2005	A1
20050059984	Chanduszko et al.	Mar 2005	A1
20050065504	Melsky et al.	Mar 2005	A1
20050080336	Byrd et al.	Apr 2005	A1
20050090818	Pike, Jr. et al.	Apr 2005	A1
20050096502	Khalili	May 2005	A1
20050096643	Brucker et al.	May 2005	A1
20050101984	Chanduszko et al.	May 2005	A1
20050107736	Landman et al.	May 2005	A1
20050119523	Starksen	Jun 2005	A1
20050124969	Fitzgerald et al.	Jun 2005	A1
20050131401	Malecki et al.	Jun 2005	A1
20050154252	Sharkey et al.	Jul 2005	A1
20050159702	Sekiguchi et al.	Jul 2005	A1
20050165272	Okada et al.	Jul 2005	A1
20050165279	Adler et al.	Jul 2005	A1
20050165391	Maguire et al.	Jul 2005	A1
20050165466	Morris et al.	Jul 2005	A1
20050197530	Wallace et al.	Sep 2005	A1
20050197623	Leeflang et al.	Sep 2005	A1
20050215895	Popp et al.	Sep 2005	A1
20050222554	Wallace et al.	Oct 2005	A1
20050222557	Baxter et al.	Oct 2005	A1
20050222558	Baxter et al.	Oct 2005	A1
20050228452	Mourlas et al.	Oct 2005	A1
20050234436	Baxter et al.	Oct 2005	A1
20050234437	Baxter et al.	Oct 2005	A1
20050267328	Blumzvig et al.	Dec 2005	A1
20050288632	Willard	Dec 2005	A1
20060009715	Khairkhahan et al.	Jan 2006	A1
20060009737	Whiting et al.	Jan 2006	A1
20060015096	Hauck et al.	Jan 2006	A1
20060022234	Adair et al.	Feb 2006	A1
20060025651	Adler et al.	Feb 2006	A1
20060025787	Morales et al.	Feb 2006	A1
20060058598	Esposito	Mar 2006	A1
20060069303	Couvillon	Mar 2006	A1
20060069313	Couvillon, Jr. et al.	Mar 2006	A1
20060074398	Whiting et al.	Apr 2006	A1
20060084839	Mourlas et al.	Apr 2006	A1
20060084945	Moll et al.	Apr 2006	A1
20060089637	Werneth et al.	Apr 2006	A1
20060111614	Saadat et al.	May 2006	A1
20060111692	Hlavka	May 2006	A1
20060122587	Sharareh	Jun 2006	A1
20060146172	Jacobsen et al.	Jul 2006	A1
20060149129	Watts et al.	Jul 2006	A1
20060149331	Mann et al.	Jul 2006	A1
20060155242	Constantz	Jul 2006	A1
20060161133	Laird et al.	Jul 2006	A1
20060167439	Kalser et al.	Jul 2006	A1
20060183992	Kawashima	Aug 2006	A1
20060195060	Navia et al.	Aug 2006	A1
20060217755	Eversull et al.	Sep 2006	A1
20060224167	Weisenburgh et al.	Oct 2006	A1
20060253113	Arnold et al.	Nov 2006	A1
20060258909	Saadat et al.	Nov 2006	A1
20060271032	Chin et al.	Nov 2006	A1
20070005019	Okishige	Jan 2007	A1
20070015964	Eversull et al.	Jan 2007	A1
20070016130	Leeflang et al.	Jan 2007	A1
20070043338	Moll et al.	Feb 2007	A1
20070043413	Eversull et al.	Feb 2007	A1
20070049923	Jahns	Mar 2007	A1
20070055142	Webler	Mar 2007	A1
20070078451	Arnold et al.	Apr 2007	A1
20070083099	Henderson et al.	Apr 2007	A1
20070083187	Eversull et al.	Apr 2007	A1
20070083217	Eversull et al.	Apr 2007	A1
20070093808	Mulier et al.	Apr 2007	A1
20070100324	Tempel et al.	May 2007	A1
20070106113	Ravo	May 2007	A1
20070106146	Altmann et al.	May 2007	A1
20070106214	Gray et al.	May 2007	A1
20070106287	O'Sullivan	May 2007	A1
20070135826	Zaver et al.	Jun 2007	A1
20070167801	Webler et al.	Jul 2007	A1
20070213584	Kim et al.	Sep 2007	A1
20070239010	Johnson	Oct 2007	A1
20070265609	Thapliyal et al.	Nov 2007	A1
20070265610	Thapliyal et al.	Nov 2007	A1
20070270639	Long	Nov 2007	A1
20070270686	Ritter et al.	Nov 2007	A1
20070282371	Lee et al.	Dec 2007	A1
20070293724	Saadat et al.	Dec 2007	A1
20070299456	Teague	Dec 2007	A1
20080009747	Saadat et al.	Jan 2008	A1
20080009859	Auth et al.	Jan 2008	A1
20080015563	Hoey et al.	Jan 2008	A1
20080015569	Saadat et al.	Jan 2008	A1
20080027464	Moll et al.	Jan 2008	A1
20080033241	Peh et al.	Feb 2008	A1
20080057106	Erickson et al.	Mar 2008	A1
20080058590	Saadat et al.	Mar 2008	A1
20080058650	Saadat et al.	Mar 2008	A1
20080058836	Moll et al.	Mar 2008	A1
20080097476	Peh et al.	Apr 2008	A1
20080183081	Lys et al.	Jul 2008	A1
20080214889	Saadat et al.	Sep 2008	A1
20080228032	Starksen et al.	Sep 2008	A1
20080234834	Meade et al.	Sep 2008	A1
20080275300	Rothe et al.	Nov 2008	A1
20080287790	Li	Nov 2008	A1
20080287805	Li	Nov 2008	A1
20080287961	Miyamoto et al.	Nov 2008	A1
20080319258	Thompson	Dec 2008	A1
20090030276	Saadat et al.	Jan 2009	A1
20090030412	Willis et al.	Jan 2009	A1
20090048480	Klenk et al.	Feb 2009	A1
20090054805	Boyle, Jr.	Feb 2009	A1
20090062790	Malchano et al.	Mar 2009	A1
20090062871	Chin et al.	Mar 2009	A1
20090076476	Barbagli et al.	Mar 2009	A1
20090076489	Welches et al.	Mar 2009	A1
20090082623	Rothe et al.	Mar 2009	A1
20090125022	Saadat et al.	May 2009	A1
20090143640	Saadat et al.	Jun 2009	A1
20090187074	Saadat et al.	Jul 2009	A1
20090203962	Miller et al.	Aug 2009	A1
20090221871	Peh et al.	Sep 2009	A1
20090227999	Willis et al.	Sep 2009	A1
20090264727	Markowitz et al.	Oct 2009	A1
20090267773	Markowitz et al.	Oct 2009	A1
20090326572	Peh et al.	Dec 2009	A1
20100004506	Saadat	Jan 2010	A1
20100004633	Rothe et al.	Jan 2010	A1
20100004661	Verin et al.	Jan 2010	A1
20100010311	Miller et al.	Jan 2010	A1
20100130836	Malchano et al.	May 2010	A1
20110021926	Spencer et al.	Jan 2011	A1
20110060227	Saadat	Mar 2011	A1
20110060298	Saadat	Mar 2011	A1
20110144576	Rothe et al.	Jun 2011	A1
20110196237	Pelissier et al.	Aug 2011	A1
20120016221	Saadat et al.	Jan 2012	A1
20120059366	Drews et al.	Mar 2012	A1
20120095332	Nitta et al.	Apr 2012	A1
20120150046	Watson et al.	Jun 2012	A1
20130172745	Choi	Jul 2013	A1
20140012074	Vazales et al.	Jan 2014	A1
20140114129	Peh et al.	Apr 2014	A1
20150094577	Saadat et al.	Apr 2015	A1
20150094582	Tanaka et al.	Apr 2015	A1
20150190036	Saadat	Jul 2015	A1
20150250382	Saadat et al.	Sep 2015	A1
20150366440	Rothe et al.	Dec 2015	A1
20160038005	Saadat et al.	Feb 2016	A1
20160095501	Saadat et al.	Apr 2016	A1
20160227989	Saadat et al.	Aug 2016	A1
20160361040	Tanaka et al.	Dec 2016	A1
20170071460	Miller et al.	Mar 2017	A1
20180000314	Saadat et al.	Jan 2018	A1
20180228350	Saadat et al.	Aug 2018	A1
20190014975	Saadat et al.	Jan 2019	A1
20190021577	Peh et al.	Jan 2019	A1
20190046013	Saadat et al.	Feb 2019	A1
20190125166	Saadat	May 2019	A1
20190307331	Saadat et al.	Oct 2019	A1
20190343373	Saadat et al.	Nov 2019	A1
20200000319	Saadat	Jan 2020	A1
20200054200	Saadat et al.	Feb 2020	A1
20200069166	Miller et al.	Mar 2020	A1
20200305693	Saadat et al.	Oct 2020	A1
20210007594	Miller et al.	Jan 2021	A1
20220338712	Saadat et al.	Oct 2022	A1

Foreign Referenced Citations (50)

Number	Date	Country
2853466	Jun 1979	DE
10028155	Dec 2000	DE
0283661	Sep 1988	EP
0301288	Feb 1989	EP
0842673	May 1998	EP
S5993413	May 1984	JP
S59181315	Oct 1984	JP
H01221133	Sep 1989	JP
H03284265	Dec 1991	JP
H05103746	Apr 1993	JP
H06507809	Sep 1994	JP
H0951897	Feb 1997	JP
H11299725	Nov 1999	JP
2001504363	Apr 2001	JP
2001258822	Sep 2001	JP
WO-9221292	Dec 1992	WO
WO-9407413	Apr 1994	WO
WO-9503843	Feb 1995	WO
WO-9740880	Nov 1997	WO
WO-9818388	May 1998	WO
WO-0024310	May 2000	WO
WO-0149356	Jul 2001	WO
WO-0172368	Oct 2001	WO
WO-0230310	Apr 2002	WO
WO-03037416	May 2003	WO
WO-03039350	May 2003	WO
WO-03053491	Jul 2003	WO
WO-03073942	Sep 2003	WO
WO-03101287	Dec 2003	WO
WO-2004043272	May 2004	WO
WO-2004080508	Sep 2004	WO
WO-2005070330	Aug 2005	WO
WO-2005077435	Aug 2005	WO
WO-2005081202	Sep 2005	WO
WO-2006017517	Feb 2006	WO
WO-2006024015	Mar 2006	WO
WO-2006083794	Aug 2006	WO
WO-2006091597	Aug 2006	WO
WO-2006126979	Nov 2006	WO
WO-2007067323	Jun 2007	WO
WO-2007079268	Jul 2007	WO
WO-2007133845	Nov 2007	WO
WO-2007134258	Nov 2007	WO
WO-2008015625	Feb 2008	WO
WO-2008021994	Feb 2008	WO
WO-2008021997	Feb 2008	WO
WO-2008021998	Feb 2008	WO
WO-2008024261	Feb 2008	WO
WO-2008079828	Jul 2008	WO
WO-2009112262	Sep 2009	WO

Non-Patent Literature Citations (92)

Entry
Avitall B., et al., “Right-Sided Driven Atrial Fibrillation in a Sterile Pericarditis Dog Model,” Pacing and Clinical Electrophysiology, 1994, vol. 17, pp. 774.
Avitall, et al. “A Catheter System to Ablate Atrial Fibrillation in a Sterile Pericarditis Dog Model,” Pacing and Clinical Electrophysiology, 1994, vol. 17, pp. 774.
Avitall, “Vagally Mediated Atrial Fibrillation in a Dog Model can be Ablated by Placing Linear Radiofrequency Lesions at the Junction of the Right Atrial Appendage and the Superior Vena Cava,” Pacing and Clinical Electrophysiology, 1995, vol. 18, pp. 857.
Baker B.M., et al., “Nonpharmacologic Approaches to the Treatment of Atrial Fibrillation and Atrial Flutter,” Journal of Cardiovascular Electrophysiology, 1995, vol. 6 (10 Pt 2), pp. 972-978.
Bhakta D., et al., “Principles of Electroanatomic Mapping,” Indian Pacing and Electrophysiology Journal, 2008, vol. 8 (1), pp. 32-50.
Bidoggia H., et al., “Transseptal Left Heart Catheterization: Usefulness of the Intracavitary Electrocardiogram in the Localization of the Fossa Ovalis,” Cathet Cardiovasc Diagn, 1991, vol. 24 (3), pp. 221-225, PMID: 1764747 [online], [retrieved Feb. 15, 2010]. Retrieved from the Internet:<URL: http://www.ncbi.nlm.nih.gov/sites/entrez>.
Bredikis J.J., et al., “Surgery of Tachyarrhythmia: Intracardiac Closed Heart Cryoablation,” Pacing and Clinical Electrophysiology, 1990, vol. 13 (Part 2), pp. 1980-1984.
Communication from the Examining Division for Application No. EP06734083.6 dated Nov. 12, 2010, 3 pages.
Communication from the Examining Division for Application No. EP06734083.6 dated Oct. 23, 2009, 1 page.
Communication from the Examining Division for Application No. EP08746822.9 dated Jul. 13, 2010, 1 page.
Co-pending U.S. Appl. No. 61/286,283, filed Dec. 14, 2009.
Co-pending U.S. Appl. No. 61/297,462, filed Jan. 22, 2010.
Cox J.L., “Cardiac Surgery for Arrhythmias,” Journal of Cardiovascular Electrophysiology, 2004, vol. 15, pp. 250-262.
Cox J.L., et al., “Five-Year Experience With the Maze Procedure for Atrial Fibrillation,” The Annals of Thoracic Surgery, 1993, vol. 56, pp. 814-824.
Cox J.L., et al., “Modification of the Maze Procedure for Atrial Flutter and Atrial Fibrillation,” The Journal of Thoracic and Cardiovascular Surgery, 1995, vol. 110, pp. 473-484.
Cox J.L., “The Status of Surgery for Cardiac Arrhythmias,” Circulation, 1985, vol. 71, pp. 413-417.
Cox J.L., “The Surgical Treatment of Atrial Fibrillation,” The Journal of Thoracic and Cardiovascular Surgery, 1991, vol. 101, pp. 584-592.
Elvan A., et al., “Radiofrequency Catheter Ablation of the Atria Reduces Inducibility and Duration of Atrial Fibrillation in Dogs,” Circulation, vol. 91, 1995, pp. 2235-2244 [online], [retrieved Feb. 4, 2013], Retrieved from the Internet: URL: http://circ.ahajournals.org/cgi/content/full/91/8/2235>.
Elvan A., et al., “Radiofrequency Catheter Ablation (RFCA) of the Atria Effectively Abolishes Pacing Induced Chronic Atrial Fibrillation,” Pacing and Clinical Electrophysiology, 1995, vol. 18, pp. 856.
Elvan, et al., “Replication of the ‘Maze’ Procedure by Radiofrequency Catheter Ablation Reduces the Ability to Induce Atrial Fibrillation,” Pacing and Clinical Electrophysiology, 1994, vol. 17, pp. 774.
European Search Report for Application No. EP07799466.3 dated Nov. 18, 2010, 9 pages.
European Search Report for Application No. EP08746822.9 dated Mar. 29, 2010, 7 Pages.
Examination Communication for Application No. EP06734083.6 dated May 18, 2010, 3 Pages.
Extended European Search Report for Application No. EP06734083.6 dated Jul. 1, 2009, 6 pages.
Extended European search report for Application No. EP20070758716 dated Feb. 28, 2011, 8 Pages.
Extended European search report for Application No. EP20070799466 dated Nov. 18, 2010, 9 Pages.
Fieguth H.G., et al., “Inhibition of Atrial Fibrillation by Pulmonary Vein Isolation and Auricular Resection—Experimental Study in a Sheep Model,” The European Journal of Cardio—Thoracic Surgery, 1997, vol. 11, pp. 714-721.
Final Office Action dated Mar. 1, 2010 for U.S. Appl. No. 12/117,655, filed May 8, 2008.
Final Office Action dated Jun. 2, 2011 for U.S. Appl. No. 12/117,655, filed May 8, 2008.
Final Office Action dated Oct. 5, 2010 for U.S. Appl. No. 11/810,850, filed Jun. 7, 2007.
Final Office Action dated May 12, 2011 for U.S. Appl. No. 11/775,771, filed Jul. 10, 2007.
Final Office Action dated Sep. 16, 2010 for U.S. Appl. No. 11/828,267, filed Jul. 25, 2007.
Hoey M.F., et al., “Intramural Ablation Using Radiofrequency Energy Via Screw-Tip Catheter and Saline Electrode,” Pacing and Clinical Electrophysiology, 1995, vol. 18, Part II, 487.
Huang, “Increase in the Lesion Size and Decrease in the Impedance Rise with a Saline Infusion Electrode Catheter for Radiofrequency,” Circulation, 1989, vol. 80 (4), II-324.
International Search Report and Written Opinion for Application No. PCT/US2007/073184, dated Aug. 12, 2012, 7 pages.
International Search Report for Application No. PCT/US2006/003288, dated Aug. 9, 2007, 1 page.
International Search Report for Application No. PCT/US2007/064195, dated Dec. 7, 2007, 1 page.
International Search Report for Application No. PCT/US2007/071226, dated Sep. 4, 2008, 1 page.
International Search Report for Application No. PCT/US2007/077429, dated Apr. 7, 2008, 1 page.
Moser K.M ., et al., “Angioscopic Visualization of Pulmonary Emboli,” Chest, 1980, vol. 77 (2), pp. 198-201.
Nakamura F., et al., “Percutaneous Intracardiac Surgery With Cardioscopic Guidance,” SPIE, 1992, vol. 1642, pp. 214-216.
Non-Final Office Action dated Jun. 7, 2011 for U.S. Appl. No. 12/323,281, filed Nov. 25, 2008.
Non-Final Office Action dated Aug. 8, 2011 for U.S. Appl. No. 12/464,800, filed May 12, 2009.
Non-Final Office Action dated Jun. 8, 2009 for U.S. Appl. No. 12/117,655, filed May 8, 2008.
Non-Final Office Action dated May 9, 2011 for U.S. Appl. No. 11/961,950, filed Dec. 20, 2007.
Non-Final Office Action dated May 9, 2011 for U.S. Appl. No. 11/961,995, filed Dec. 20, 2007.
Non-Final Office Action dated May 9, 2011 for U.S. Appl. No. 11/962,029, filed Dec. 20, 2007.
Non-Final Office Action dated Jun. 10, 2010 for U.S. Appl. No. 11/560,742, filed Nov. 16, 2006.
Non-Final Office Action dated Apr. 11, 2011 for U.S. Appl. No. 11/763,399, filed Jun. 14, 2007.
Non-Final Office Action dated Mar. 11, 2011 for U.S. Appl. No. 11/848,202, filed Aug. 30, 2007.
Non-Final Office Action dated May 11, 2011 for U.S. Appl. No. 11/828,267, filed Jul. 25, 2007.
Non-Final Office Action dated Apr. 12, 2011 for U.S. Appl. No. 12/499,011, filed Jul. 7, 2009.
Non-Final Office Action dated Jan. 14, 2010 for U.S. Appl. No. 11/828,267, filed Jul. 25, 2007.
Non-Final Office Action dated Dec. 16, 2010 for U.S. Appl. No. 12/117,655, filed May 8, 2008.
Non-Final Office Action dated Mar. 16, 2010 for U.S. Appl. No. 11/810,850, filed Jun. 7, 2007.
Non-Final Office Action dated Feb. 18, 2011 for U.S. Appl. No. 12/947,198, filed Nov. 16, 2010.
Non-Final Office Action dated Feb. 18, 2011 for U.S. Appl. No. 12/947,246, filed Nov. 16, 2006.
Non-Final Office Action dated May 20, 2011 for U.S. Appl. No. 11/775,819, filed Jul. 10, 2007.
Non-Final Office Action dated May 20, 2011 for U.S. Appl. No. 11/877,386, filed Oct. 23, 2007.
Non-Final Office Action dated Jul. 21, 2010 for U.S. Appl. No. 11/687,597, filed Mar. 16, 2007.
Non-Final Office Action dated Apr. 22, 2011 for U.S. Appl. No. 12/367,019, filed Feb. 6, 2009.
Non-Final Office Action dated May 23, 2011 for U.S. Appl. No. 11/775,837, filed Jul. 10, 2007.
Non-Final Office Action dated Nov. 24, 2010 for U.S. Appl. No. 11/848,429, filed Aug. 31, 2007.
Non-Final Office Action dated Nov. 24, 2010 for U.S. Appl. No. 12/464,800, filed May 12, 2009.
Non-Final Office Action dated Apr. 25, 2011 for U.S. Appl. No. 11/959,158, filed Dec. 18, 2007.
Non-Final Office Action dated Feb. 25, 2010 for U.S. Appl. No. 11/259,498, filed Oct. 25, 2005.
Non-Final Office Action dated Feb. 25, 2011 for U.S. Appl. No. 11/848,207, filed Aug. 30, 2007.
Non-Final Office Action dated Apr. 26, 2011 for U.S. Appl. No. 11/848,532, filed Aug. 31, 2007.
Non-Final Office Action dated Apr. 27, 2011 for U.S. Appl. No. 11/828,281, filed Jul. 25, 2007.
Non-Final Office Action dated Aug. 27, 2010 for U.S. Appl. No. 11/775,771, filed Jul. 10, 2007.
Non-Final Office Action dated Dec. 27, 2010 for U.S. Appl. No. 12/026,455, filed Feb. 5, 2008.
Notice of Allowance dated Feb. 3, 2011 for U.S. Appl. No. 11/560,732, filed Nov. 16, 2006.
Notice of Allowance dated Jun. 13, 2011 for Japanese Application No. 2007-554156 filed Jan. 30, 2006.
Notice of Allowance dated Nov. 15, 2010 for U.S. Appl. No. 11/259,498, filed Oct. 25, 2005.
Notice of Allowance dated Nov. 15, 2010 for U.S. Appl. No. 11/560,742, filed Nov. 16, 2006.
Notice of Allowance dated Feb. 24, 2011 for U.S. Appl. No. 11/560,732, filed Mar. 16, 2007.
Notice of Allowance dated Feb. 24, 2011 for U.S. Appl. No. 11/687,597, filed Mar. 16, 2007.
Office Action dated Feb. 15, 2011 for Japanese Application No. 2007-554156 filed Jan. 30, 2006.
Office Action dated Apr. 27, 2011 for Japanese Application No. 2009-500630 filed Mar. 16, 2007.
Pappone C., et al., “Circumferential Radiofrequency Ablation of Pulmonary Vein Ostia,” Circulation, 2000, vol. 102, pp. 2619-2628.
Sethi K.K., et al., “Transseptal catheterization for the electrophysiologist: modification with a ‘view’,” Journal of Interventional Cardiac Electrophysiology, 2001, vol. 5 (1), pp. 97-99.
Supplemental European Search Report for Application No. EP07758716 dated Feb. 28, 2011, 8 Pages.
Supplementary European search report for Application No. EP07812146.4 dated Nov. 18, 2010, 8 Pages.
Supplementary European Search Report for Application No. EP07841754, dated Jun. 30, 2010, 6 pages.
Thiagalingam A., et al., “Cooled Needle Catheter Ablation Creates Deeper and Wider Lesions than Irrigated Tip Catheter Ablation,” Journal of Cardiovascular Electrophysiology, 2005, vol. 16(5), pp. 1-8.
Uchida Y., “Developmental History of Cardioscopes”, in: Coronary Angioscopy, Chapter 19, Futura Publishing Company, Inc., 2001, pp. 187-197.
Willkampf F.H., et al., “Radiofrequency Ablation with a Cooled Porous Electrode Catheter,” JACC, Abstract, 1988, vol. 11 (2), pp. 17A.
Written Opinion for Application No. PCT/US2006/003288, dated Aug. 9, 2007, 6 pages.
Written Opinion for Application No. PCT/US2007/064195, dated Dec. 7, 2007, 5 pages.
Written Opinion for Application No. PCT/US2007/071226, dated Sep. 4, 2008, 4 page.
Written Opinion for Application No. PCT/US2007/077429, dated Apr. 7, 2008, 5 pages.
Vertut, J, and Coiffet, P., “Robot Technology: Teleoperation and Robotics Evolution and Development,” English translation, Prentice-Hall, Inc., Inglewood Cliffs, NJ, USA 1986, vol. 3A, 332 pages.

Related Publications (1)

	Number	Date	Country
	20190008360 A1	Jan 2019	US

Provisional Applications (2)

	Number	Date	Country
	60916640	May 2007	US
	60824421	Sep 2006	US

Continuations (2)

	Number	Date	Country
Parent	12464800	May 2009	US
Child	16117993		US
Parent	11848429	Aug 2007	US
Child	12464800		US

Precision control systems for tissue visualization and manipulation assemblies

Information

Patent Number

Date Filed

Date Issued

Inventors

Original Assignees

Examiners

Agents

CPC

Field of Search

CPC

International Classifications

Term Extension

Abstract